

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 3/12, 3/28	A1	(11) International Publication Number: WO 91/16335 (43) International Publication Date: 31 October 1991 (31.10.91)
(21) International Application Number: PCT/US91/02766 (22) International Filing Date: 25 April 1991 (25.04.91) (30) Priority data: 515,474, 26 April 1990 (26.04.90) US (71) Applicant: CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US). (72) Inventors: NASCIMENTO, Carlos, George ; 1907 South Forest Hill, Danville, CA 94526 (US). CALDERON-CACIA, Maria, Dolores ; 245800 Industrial Boulevard, No. S2241, Hayward, CA 94545 (US). (74) Agents: ROBINS, Roberta, L. et al.; Irell & Manella, 545 Middlefield Road, Suite 200, Menlo Park, CA 94025 (US).		(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i>
(54) Title: GLYCOSYLATED PDGF (57) Abstract Hyperglycosylated PDGF and methods of producing and isolating the same are disclosed. The hyperglycosylated PDGF displays markedly increased activity when compared to a less or nonglycosylated counterpart. The hyperglycosylated PDGF can be produced recombinantly in yeast and isolated from the less glycosylated fraction using lectin affinity chromatography.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

5 GLYCOSYLATED PDGF

Description

Technical Field

10 The instant invention relates generally to PDGF. More particularly, the present invention relates to a hyperglycosylated PDGF with increased biological activity, and methods of making and isolating the same.

15 Background

 Platelet Derived Growth Factor (PDGF) is the major mitogen in serum for mesenchymal-derived cells. PDGF promotes cell division of a variety of cells including smooth muscle cells, fibroblasts, and glial
20 cells. PDGF is stored in platelet alpha-granules and is released locally during platelet activation when blood vessels are injured. It is also a potent chemoattractant for monocytes, neutrophils, fibroblasts, and smooth muscle cells. These activities make PDGF an important
25 component in tissue repair processes.

 Native PDGF consists of dimers of homologous polypeptide chains, denoted A and B. Johnsson et al., Biochem Biophys Res Commun (1982) 104:66-74. The mature A and B monomers exhibit nearly 60% homology. Whether
30 native PDGF is a heterodimer or a mixture of homodimers is not known, however, the dimeric structure is functionally important, since reduction of the disulfide bonds irreversibly destroys the biological activity of PDGF.

35

The complete primary structure of the PDGF A-chain precursor has been deduced from its complementary DNA sequence. Betsholtz et al., Nature (1986) 320:695-699. Furthermore, Heldin et al., Nature (1986),
5 describes an osteosarcoma-derived growth factor (ODGF) that is structurally related to putative PDGF A-chain homodimer and studies on ODGF suggest that the PDGF A-chain homodimer would exhibit biological activity.

Similarly, the amino acid sequence of the
10 B-chain precursor has been described. Collins et al., Nature (1985) 316:748-750. The B-chain is derived by proteolytic processing of this precursor which is encoded by the c-sis gene, the cellular counterpart to the transforming gene v-sis of simian sarcoma virus (SSV).
15 The SSV v-sis gene encodes a protein called p28sis, with a molecular weight under nonreducing conditions of about 24 kDa (Robbins et al., Nature (1983) 305:605-608). p28sis is highly homologous (approximately 96%) to the PDGF B-chain. Mitogenic activity of p28sis and the
20 B-chain homologous region has been demonstrated in yeast expression products. Kelly et al., EMBO J (1985) 4:3399-3405.

PDGF and analogs thereof have been expressed in mammalian cell systems. See, e.g., King et al., Proc
25 Natl Acad Sci USA (1985) 82:5295-5299; Clarke et al., Nature (1984) 308:464-467; Gazit et al., Cell (1984) 39:89-97; and Josephs et al., Science (1984) 225:636-639. Additionally, Kelly et al., EMBO J (1985) 4:3399-3405, and U.S. patent nos. 4,766,073, 4,769,328 and
30 4,889,919 disclose methods for expressing PDGF A- and B-chain analogs in yeast, and homodimers and heterodimers thereof. European Patent Application 88302116.4 describes methods for purification of recombinant PDGF B-chain and U.S. patent no. 4,479,896 describes the
35 recovery of PDGF peptides from human platelets.

Deule et al., J Biol Chem (1981) 256:8896-8899, found that PDGF A and B, isolated from human platelets, are glycoproteins. Hannick et al., Mol Cell Biol (1986) 6:1343-1348, localized the v-sis gene product to the endoplasmic reticulum-Golgi compartment and postulated that the protein was glycosylated, based on a reduction of molecular weight thereof after treatment with a glycosylation inhibitor or a deglycosylating agent. Klein et al., Virology (1988) 64:403-410, found that cells transformed with SSV release a highly glycosylated molecule termed gp200sis, in addition to p28sis, which is recognized by anti-PDGF serum and appears to act as a PDGF-like growth factor. However, none of the above-described references disclose the isolation of a hyperglycosylated PDGF molecule displaying increased biological activity.

Glycoproteins produced in eucaryots contain carbohydrate chains linked to Asn amino acid residues, in the case of N-linked oligosaccharides, and Ser or Thr residues, in the case of O-linked sugars. Additionally, the carbohydrate chains found on glycoproteins produced in yeast consist primarily of mannose moieties. Certain yeast species also add terminal galactose and N-acetylglucosamine residues to the sugar molecule. PDGF A-chain contains both putative N- and O-glycosylation sites while the PDGF B-chain includes several possible O-linked glycosylation sites.

Disclosure of the Invention

The present invention is based on the unexpected discovery of a hyperglycosylated PDGF B homodimer which, when isolated from a heterogenous mixture, displays dramatically increased biological activity.

Accordingly, in one embodiment, the instant invention is directed to hyperglycosylated PDGF.

In another embodiment, the invention is directed to a method of producing hyperglycosylated PDGF comprising:

(a) providing a mixture containing a hyperglycosylated PDGF fraction and a less glycosylated PDGF fraction; and

(b) isolating the hyperglycosylated PDGF from the mixture.

In particularly preferred embodiments, the hyperglycosylated PDGF is PDGF B-B homodimer having at least 17 moles of mannose per mole of dimer and the hyperglycosylated B-B homodimer is isolated from the less glycosylated fraction using lectin affinity chromatography.

These and other embodiments of the present invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.

Brief Description of the Figures

Figure 1 shows the nucleotide sequence and corresponding amino acid sequence for one form of the PDGF A-chain polypeptide (designated 13-1).

Figure 2 shows the nucleotide sequence and corresponding amino acid sequence for a second form of the PDGF A-chain polypeptide (designated D1).

Figure 3 depicts the nucleotide sequence and corresponding amino acid sequence of a PDGF B-chain polypeptide.

Figure 4 shows the nucleotide sequence and deduced amino acid sequence of the 13-1 A-chain precursor. The boxed portion designates the mature polypeptide.

Figure 5 depicts the nucleotide sequence and deduced amino acid sequence of the D1 A-chain precursor. The boxed portion designates the mature polypeptide.

Figure 6 is a diagram of plasmid pYAGL7PB,
5 described in the examples.

Figure 7 is a diagram of plasmid pYpA6,
described in the examples.

Figure 8 is a diagram of plasmid pYpA134,
described in the examples.

Figure 9 is a diagram of plasmid pAB24,
10 described in the examples.

Figure 10 is a graph showing the effect of the degree of glycosylation of PDGF B-B homodimer (determined by ConA affinity chromatography) on mitogenic activity.

Figure 11 is a typical chromatogram obtained when hyperglycosylated PDGF and less glycosylated PDGF are separated using ConA affinity chromatography.

Figure 12 shows the in vivo incorporation of ³H-mannose into PDGF B-producing cells.

Figure 13 is the nucleotide sequence of the SV40 region used to make plasmid pSV7d, described in the examples.

Figure 14 is a map of the plasmid pSV7d,
25 described in the examples.

Detailed Description

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of protein chemistry, molecular biology,
30 microbiology and recombinant DNA technology, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Scopes, R.K., Protein Purification Principles and Practice, 2nd ed. (Springer-Verlag 1987); Methods in Enzymology (S.
35 Colowick and N. Kaplan eds., Academic Press, Inc.);

Maniatis, Fritsch & Sambrook, Molecular Cloning: A Laboratory Manual (1982); Oligonucleotide Synthesis (M.J. Gait ed. 1984); and Handbook of Experimental Immunology, Vols. I-IV (D.M. Weir and C.C. Blackwell eds., 1986, Blackwell Scientific Publications).

All patents, patent applications, and publications mentioned herein, whether supra or infra, are hereby incorporated by reference.

10 A. Definitions

In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.

As used herein, the term "PDGF" refers to any active form of PDGF (as determined by the assays described in the Experimental section). Thus, the PDGF molecule may be either an A-A, B-B, or A-B dimer, or fusion proteins thereof, the individual chains having a primary sequence as depicted in Figures 1, 2, or 3 and analogs of these amino acid sequences which are substantially homologous and functionally equivalent thereto. The term "substantially homologous" intends that the number of amino acid variations (including substitutions, additions and/or deletions) in the sequence be less than about 10, preferably less than about 3. The term "functionally equivalent" refers to sequences of an analog which define a chain that will produce a protein having the biological activity of PDGF (as measured by the assay described in Example 5). Thus, the A- and B-chain amino acid sequences need not be identical to the depicted sequences.

"A composition of hyperglycosylated" or "highly glycosylated" PDGF as used herein refers to an active composition comprising at least an average of 10 moles of carbohydrate per mole of dimer, more preferably an

average of 12-15 moles of carbohydrate per mole of dimer, and most preferably an average of 17 moles of carbohydrate per mole of dimer. The composition can include either nonglycosylated or less glycosylated PDGF forms so long as the average amount of carbohydrate per mole of dimer is as stated above. The carbohydrate present on the hyperglycosylated PDGF can be any carbohydrate that will bind the molecule and that does not destroy the biological activity of the hyperglycosylated PDGF composition. Examples of sugar moieties useful in the instant invention are described more fully below. These sugars can be added as monomeric units or as oligomers, as described below. "Less glycosylated" PDGF is a PDGF molecule having less carbohydrate moieties bound thereto than the hyperglycosylated PDGF described above.

A composition containing A is "substantially free of" B when at least 85% by weight of the total A+B in the composition is A. Preferably, A comprises at least about 90% by weight of the total of A+B in the composition, more preferably at least about 95% or even 99% by weight.

The term "recombinant" as used herein to characterize DNA encoding PDGF A- or B-chain polypeptides intends DNA of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation is either a DNA sequence not occurring in nature or a DNA sequence linked to DNA other than that to which it is linked in nature.

A "replicon" is any genetic element (e.g., a plasmid, a chromosome, a virus) that behaves as an autonomous unit of polynucleotide replication within a cell; i.e., capable of replication under its own control.

A "vector" is a replicon in which another polynucleotide segment is attached, so as to bring about

the replication and/or expression of the attached segment. An "expression vector" refers to a vector capable of autonomous replication or integration and contains control sequences which direct the transcription and translation of the PDGF A- or B-chain DNA in an appropriate host.

A "coding sequence" is a polynucleotide sequence which is transcribed and/or translated into a polypeptide.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase and initiating transcription of a downstream (i.e., in the 3' direction) coding sequence.

A coding sequence is "under the control" of the promoter sequence in a cell when transcription of the coding sequence results from the binding of RNA polymerase to the promoter sequence; translation of the resulting mRNA then results in the polypeptide encoded within the coding sequence.

"Operably linked" refers to a juxtaposition wherein the components are configured so as to perform their usual function. Thus, control sequences operably linked to a coding sequence are capable of effecting the expression of the coding sequence.

"Control sequences" refers to those sequences which control the transcription and/or translation of the coding sequence(s); these may include, but are not limited to, promoter sequences, transcriptional initiation and termination sequences, and translational initiation and termination sequences, and translational initiation and termination sequences. In addition, "control sequences" refers to sequences which control the processing of the polypeptide encoded within the coding sequence; these may include, but are not limited to

35

sequences controlling secretion, protease cleavage, and glycosylation of the polypeptide.

A "signal sequence" can be included before the coding sequence. This sequence encodes a signal peptide, N-terminal to the polypeptide, that communicates to the host cell to direct the polypeptide to the cell surface or secrete the polypeptide into the media, and this signal peptide is clipped off by the host cell before the protein leaves the cell. Signal sequences can be found associated with a variety of proteins native to procaryots and eucaryots. For instance, alpha-factor, a native yeast protein, is secreted from yeast, and its signal sequence can be attached to heterologous proteins to be secreted into the media (See U.S. Patent 4,546,082, EPO 0 116 201, publication date 12 January 1983; U.S. Patent Application Ser. No. 522,909, filed 12 August 1983). Further, the alpha-factor and its analogs have been found to secrete heterologous proteins from a variety of yeast, such as *Saccharomyces* and *Kluyveromyces*, (EPO 88312306.9 filed 23 December 1988; U.S. Patent Application Ser. No. 139,682, filed 30 December 1987, and EPO Pub. No. 0 301 669, publication date 1 February 1989).

"Transformation" is the insertion of an exogenous polynucleotide into a host cell. The exogenous polynucleotide may be maintained as a plasmid, or alternatively, may be integrated within the host genome.

B. General Methods

Central to the instant invention is the discovery that PDGF, isolated from eucaryotic cells, exists as a heterogenous mixture of hyperglycosylated and less glycosylated forms, as defined above. These glycoproteins can be separated and the resulting hyperglycosylated population exhibits surprisingly

greater mitogenic activity than the less glycosylated PDGF.

PDGF A-A, B-B or A-B dimers can be isolated or produced recombinantly in suitable cell expression systems, under conditions favoring glycosylation, according to the protocols described herein. Methods for producing recombinant PDGF are also explained in commonly owned, copending U.S. Patent Application ser. no. 041,299, filed 4 April 1987, the disclosure of which is incorporated herein by reference in its entirety. Highly glycosylated fractions are separated from less glycosylated proteins by the method described below to yield a hyperglycosylated PDGF fraction. Alternatively, PDGF dimers can be synthetically produced, using protein synthesis techniques well known in the art and explained in more detail below.

Production of Recombinant Hyperglycosylated PDGF

20 1. Recombinant PDGF DNA

The recombinant PDGF of the invention consists of highly glycosylated A-A, B-B, or A-B dimers. Two amino acid sequences for the PDGF A-chain are shown in Figures 1 and 2, respectively. Figure 3 depicts an amino acid sequence for the PDGF B-chain. The invention also encompasses analogs of these amino acid sequences which are substantially homologous and functionally equivalent thereto, as defined above. DNA sequences for use in eucaryotic expression systems, encoding the PDGF A-chain, are shown in Figures 1 and 2, respectively, while that for the PDGF B-chain is shown in Figure 3.

The recombinant PDGF A- or B-chain DNA may be genomic, cDNA or synthetic DNA. By way of example, DNA encoding the PDGF A- or B-chain can be obtained from a cDNA library prepared from mRNA of a PDGF-producing cell

line. The library can be probed with oligonucleotide sequences based on the sequences disclosed in the figures. Clones that hybridize with the probes can be used to probe human genomic libraries to obtain analogous genomic DNA encoding the PDGF polypeptides. Based on the amino acid sequences illustrated, synthetic genes encoding the PDGF A- and B-chain may be prepared in vitro by synthesizing individual overlapping complementary oligonucleotides and filling in single stranded nonoverlapping portions using DNA polymerase in the presence of the deoxyribonucleotide triphosphates.

2. Cloning PDGF DNA

The PDGF A- and B-chain DNA can be cloned into any suitable replicon to create a vector, and thereby be maintained in a composition which is substantially free of vectors that do not contain the PDGF gene of interest (e.g., other clones derived from the library). Numerous cloning vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of choice. However, preferred are those vectors for expression in eucaryotic cells, most preferably yeast cells, since these systems provide glycosylated products. The PDGF products of the instant invention can also be produced in bacteria and later glycosylated with any suitable sugar moieties, using techniques known in the art, and described in more detail below.

Numerous cloning vectors are known to those of skill in the art and the selection of an appropriate cloning vector and host cells for use therewith is a matter of choice. Examples of vectors for cloning and host cells which they transform (in parenthesis) include the bacteriophage lambda (E. coli); pBR322 (E. coli); pACYC 177 (E. coli); pKT 230, pGV1106, and pLAFR1 (all useful in gram-negative bacteria); pME290 (non-E. coli

gram-negative bacteria), pHV 14 (E. coli and Bacillus subtilis), pBD9 (Bacillus), pIJ61 (Streptomyces), pUC6 (Streptomyces), actinophage C31 (Streptomyces), YIp5 (Saccharomyces), YCp19 (Saccharomyces), and bovine
5 papilloma virus (mammalian cells).

3. Expression of PDGF DNA

The polynucleotide sequence encoding the PDGF A- or B-chain polypeptides are expressed by inserting the
10 sequence into an appropriate replicon thereby creating an expression vector, and introducing the resulting expression vector into a compatible host.

In creating an expression vector the sequence encoding the PDGF A- or B-chain polypeptide is located in
15 the vector with the appropriate control sequences. The positioning and orientation of the coding sequence with respect to the control sequences is such that the coding sequence is transcribed under the control of the control sequences: i.e., the promoter will control the
20 transcription of the mRNA derived from the coding sequence; and the ribosomes will bind at the ribosomal binding site to begin the translational process; and the stop codon used to terminate translation will be upstream from the transcriptional termination codon. Commonly
25 used procaryotic control sequences include such commonly used promoters as the β -lactamase (penicillinase) and lactose (lac) promoter systems (Chang et al., Nature (1977) 198:1056) and the tryptophan (trp) promoter system (Goeddel et al., Nucleic Acids Res (1980) 8:4057) and the
30 lambda-derived P_L promoter and N-gene ribosome binding site (Shimatake et al., Nature (1981) 292:128). Control sequences for yeast vectors include promoters for the synthesis of glycolytic enzymes (Hess et al., J Adv Enzyme Reg (1968) 7:149; Holland et al., Biochemistry
35 (1978) 17:4900). Additional promoters known in the art

include the promoter for 3-phosphoglycerate kinase (Hitzeman et al., J Biol Chem (1980) 255:2073). Other promoters, which have the additional advantage of transcription controlled by growth conditions and/or genetic background are the promoter regions for alcohol dehydrogenase 2 (ADH2), isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, the α -factor system and enzymes responsible for maltose and galactose utilization. It is also believed that terminator sequences are desirable at the 3' end of the coding sequences. Such terminators are found in the 3' untranslated region following the coding sequences in yeast-derived genes. Expression vectors for mammalian cells such as VERO, HeLa or CHO cells ordinarily include promoters and control sequences compatible with such cells as, for example, the commonly used early and late promoters from Simian Virus 40 (SV40) (Fiers et al., Nature (1978) 273:113), or other viral promoters such as those derived from polyoma, Adenovirus 2, bovine papilloma virus, or avian sarcoma viruses. The controllable promoter, hMTII (Karin, M., et al., Nature (1982) 299:797-802) may also be used.

In addition to control sequences, it may be desirable to add regulatory sequences which allow for regulation of the expression of the PDGF A- or B-chain gene relative to the growth of the host cell. Examples of regulatory systems are those which cause the expression of a gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. In procaryotic systems these would include the lac and trp operator systems. In eucaryotic systems induction can occur in metallothionein genes with heavy metals and the mouse mammary tumor virus (MMTV) system with steroids. In these cases, the sequence encoding the PDGF A-chain

polypeptides would be placed in tandem with the regulatory element.

There are also selective elements which give rise to DNA amplification which in turn can result in higher levels of specific protein production. In higher eucaryotic systems these include the dihydrofolate reductase gene (dhfr) which is amplified in the presence of methotrexate, and adenosine deaminase (ADA) in the presence of deoxycorformycin. In other eucaryotic systems, such as yeast, the uracil gene (ura) and/or the leucine gene (leu) can be used as selectable markers. For amplification in such systems, copper and tunicamycin resistance genes can be included in the vector and amplification can be achieved by the inclusion of copper and tunicamycin in the expression medium. In these cases the sequence encoding the PDGF A- or B-chain polypeptides may either be present on the same plasmid or merely be cotransfected together with the selectable element to allow for integration within the host cell genome near each other.

Other types of regulatory elements may also be present in the vector, i.e., those which are not necessarily in tandem with the sequence encoding PDGF A- or B-chain. An example is the SV40 enhancer sequence, which, by its mere presence, causes an enhancement of expression of genes distal to it.

Modification of the sequence encoding PDGF A- or B-chain, prior to its insertion into the replicon, may be desirable or necessary, depending upon the expression system chosen. For example, in some cases, it may be necessary to modify the sequence so that it may be attached to the control sequences with the appropriate orientation, i.e., to maintain the reading frame. It may also be desirable to add sequences which cause the secretion of the polypeptide from the host organism, with

subsequent cleavage of the secretory signal. The techniques for modifying nucleotide sequences utilizing cloning are well known to those skilled in the art. They include, e.g., the use of restriction enzymes, of enzymes
5 such as Bal31, to remove excess nucleotides, and of chemically synthesized oligonucleotides for use as adapters, to replace lost nucleotides, and in site-directed mutagenesis.

The appropriately modified sequence encoding
10 the PDGF A- or B-chain polypeptide may be ligated to the control sequences prior to insertion into a vector. Alternatively, the coding sequence can be cloned directly into an expression vector which already contains the control sequences and an appropriate restriction site.
15 For expression of the PDGF A- or B-chain polypeptide in procaryots and in yeast, the control sequences will necessarily be heterologous to the coding sequence. In cases where the PDGF A- or B-chain gene is to be expressed in cell lines derived from vertebrates, the
20 control sequences may be either heterologous or homologous, depending upon the particular cell line.

Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride,
25 as described by Cohen, S.N., Proc Natl Acad Sci (USA) (1972) 69:2110, or the RbCl₂ method described in Maniatis et al., Molecular Cloning: A Laboratory Manual (1982) Cold Spring Harbor Press, p. 254, and Hanahan, D., J Mol Biol (1983) 166:557-580, may be used for procaryots or
30 other cells which contain substantial cell wall barriers. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology (1978) 52:546, optionally as modified by Wigler, M., et al., Cell (1979) 16:777-785, may be used.
35 Transformations into yeast may be carried out according

to the method of Beggs, J.D., Nature (1978) 275:104-109, or of Hinnen, A., et al., Proc Natl Acad Sci (USA) (1978) 75:1929.

Other systems for expression of eucaryotic or viral genomes include insect cells and vectors suitable for use in these cells. These systems are known in the art, and include, for example, insect expression transfer vectors derived from the baculovirus Autographa californica nuclear polyhedrosis virus (AcNPV), which is a helper-independent, viral expression vector. Expression vectors derived from this system usually use the strong viral polyhedrin gene promoter to drive expression of heterologous genes. Methods for the introduction of heterologous DNA into the desired site in the baculovirus are known in the art. (See Summer and Smith, Texas Agricultural Experiment Station Bulletin No. 1555; Smith et al., Mol and Cell Biol (1983) 3:2156-2165; and Luckow and Summers, Virology (1989) 17:31). For example, the insertion can be into a gene such as the polyhedrin gene, by homologous recombination; insertion can also be into a restriction enzyme site engineered into the desired baculovirus gene. Sequences encoding signal peptides can also be used in these expression systems since these peptides are recognized by insect cells and will cause the secretion of the expressed product into the expression medium.

Transformed cells are then grown under conditions which permit expression of the PDGF A- or B-chain gene and assembly of the expression product into a biologically active PDGF (i.e., into a dimeric form). In addition to producing recombinant PDGF A-chain or B-chain homodimers, the present invention permits production of heterodimers of PDGF A-chain and PDGF B-chain by co-expressing the genes for both PDGF A-chain and PDGF B-chain through use of separate vectors or a

single vector than contains an A-chain gene and the B-chain gene. The recombinant PDGF protein thus synthesized is then isolated from the host cells and purified. If the expression system secretes the PDGF into the growth media, the PDGF is isolated directly from the media. If the recombinant PDGF is not secreted, it is isolated from cell lysates. The selection of the appropriate growth conditions and recovery methods are within the skill of the art. With regard to purification, see for instance EPA Publication No. 0177957 and Nature (1986) 319:511-514.

It has been found that PDGF isolated from yeast expression systems exists in a heterogenous state. That is, both a hyperglycosylated fraction and a less glycosylated fraction were found in expression products from yeast. These fractions exhibit differing biological activity, as determined by the mitogenic assay described herein--the more highly glycosylated fraction and mixtures containing a higher percentage of the highly glycosylated fraction, being more active. The two fractions can be further separated, as described below, to yield a purer form of hyperglycosylated PDGF.

If the PDGF has been expressed in systems which produce nonglycosylated products, i.e. in bacteria, the proteins can be glycosylated by the addition of oligosaccharide units to appropriate glycosylation sites. It is known that O-glycoproteins are formed by linkages between Ser and Thr with a variety of sugars including galactose, xylose, mannose, and fructose, among others. Montreuil, J., Advances in Carbohydrate Chemistry and Biochemistry, Vol. 37, pp. 157-223 (Academic Press 1980). Other sugars that will find use with the instant invention include but are not limited to aldoses and ketoses such as glyceraldehyde, erythrose, ribose, allose, altrose, arabinose, glucose, threose, gulose, idose, lyxose, talose, and

derivatives thereof such as glycosides, glycosylamines, O-acyl derivatives, O-methyl derivatives, amino sugars, among others. These sugars can be present as mono-, di-, or polysaccharides.

5 N-linked glycosylation typically occurs between a sugar and an Asn residue at locations in a peptide chain having the amino acid sequence Asn-X-Ser(or Thr), where X can be any of the 20 amino acids. Sugars typically added in N-linked glycosylation include fucose,
10 galactosamine, glucosamine, galactose, glucose, and mannose, as well as those listed above, with galactosamine being the usual linking sugar.

Therefore, potential O-linked glycosylation sites of the PDGF A-chain can be found at positions Ser-
15 1, Thr-12, Thr-14, Ser-22, Thr-27, Ser-28, Thr-44, Thr-49, Ser-50, Ser-51, Ser-57, Ser-63, Thr-95, Thr-96, Ser-97, Thr-107 of Figure 1 and, additionally at Ser-113 and Thr-125 of Figure 2. Possible N-glycosylation sites for the A-chain occur at Asn-48 of Figures 1 and 2. The PDGF
20 B-chain contains a number of putative O-glycosylation sites found at amino acid residues Ser-1, Ser-4, Thr-6, Thr-18, Thr-20, Ser-26, Thr-33, Ser-50, Thr-63, Thr-88, Thr-90, Thr-101, and Thr-109, as depicted in Figure 3. However, there appear to be no N-glycosylation sites in
25 the B peptide. Thus, sugars can be linked to any of these positions which are sterically accessible and in such a way so that the biological activity of the molecule is enhanced.

Furthermore, the carbohydrate moiety added to
30 the PDGF molecule can consist of a single sugar or an oligosaccharide chain composed of either the same monomeric unit or a variety of sugars.

Oligosaccharides for use with the instant invention can be synthesized using techniques known in
35 the art. See, e.g., Hubbard et al., Ann Rev Biochem

(1981) 50:555-583 and Solid-Phase Synthesis (E.C. Blossey and D.C. Neckers eds., 1975), the disclosures of which are incorporated herein by reference. Specifically, for solid-phase oligosaccharide synthesis, an activated monomer unit, protected by a temporary blocking group such a p-nitrobenzoate at one hydroxyl, and a persistent blocking group such as a benzyl at the remaining hydroxyls, is coupled to a suitably functionalized allylic alcohol resin. The temporary blocking group is removed under mild conditions which leave the persistent blocking group attached. A simple alcoholysis reaction is then performed to attach a new monomer unit to the reactive end of the unit previously attached to the resin. Further steps include the sequential deblocking and coupling until an oligomer of the desired length is obtained. The oligomer is then cleaved from the support by oxidation and persistent blocking groups removed from the soluble derivative.

The synthesized oligosaccharide or monomeric sugar can be added to the PDGF polypeptide by the addition of the sugar along with appropriate enzymes, according to methods well known in the art. See, e.g., Ann Rev Biochem (1987) 56:915-944 and FEBS 0620 (July 1983) 158(2):335-338. Any sugar or combination of sugars, shown to increase PDGF activity as determined herein, in an amount equivalent to the increase seen when at least 10 moles of carbohydrate are present per mole of PDGF dimer, will find use with the instant invention. Methods for quantitating as well as identifying the sugar moieties of glycoproteins are known in the art. Such a determination can be made using a Dio LC GlycoProtein Instrument (Dionex, Sunnyvale, CA.), as well as by chemical determination using periodate, classical paper chromatography on silica plates, and incorporation of radioactive sugars into the polypeptide chain.

4. Purification of Hyperglycosylated PDGF

As explained above, isolated, recombinantly produced PDGF has been found to exist in a heterogenous state with respect to glycosylation. The heterogenous mixture can be further purified by separating the two PDGF forms, using agents known to react with carbohydrate-containing molecules. For example, the heterogenous expression product can be subjected to affinity chromatography or affinity electrophoresis, using ligands, such as lectins, useful for separating glycoproteins. Particularly useful is a column packed with a lectin-agarose resin, such as concanavalin A (ConA) sepharose. The more highly glycosylated PDGF will bind the column and can be competed off using an appropriate sugar. The sugar used will depend on the carbohydrate moieties present on the PDGF. For example, as explained in more detail below, the hyperglycosylated yeast expression product was found to contain mannose moieties and therefore, a mannose sugar can be added to the elution buffer. The hyperglycosylated PDGF can also be recovered from the column by using an enzyme that will cleave the linkage formed between the sugar moieties of PDGF and the lectin. Enzymes useful with particular sugar moieties are well known in the art.

5. Synthetic Production of Glycosylated PDGF

PDGF dimers can be produced synthetically, based on the amino acid sequences shown in Figures 1, 2 and 3, using protein synthesis techniques well known in the art, such as solid or solution phase peptide synthesis. Summaries of common synthetic techniques can be found in Stewart, J.M., and Young, J.D., Solid Phase Peptide Synthesis, 2nd ed. (Pierce Chemical Co. 1984) and Barany, G., and Merrifield, R.B., The Peptides: Analysis,

Synthesis, Biology, Vols. 1 and 2 (E. Gross and J. Meienhofer eds., Academic Press 1980), and Bodansky, M., Principles of Peptide Synthesis, (Springer-Verlag 1984), the disclosures of which are incorporated herein by
5 reference in their entirety.

In general, these methods consist of the sequential addition of individual amino acids to a growing chain. The amino or carboxyl group of the first amino acid is typically protected or derivatized and this
10 group is either attached to an inert solid support or used directly in solution. The next amino acid in the sequence having the complementary (amino or carboxyl) group suitably protected, is then added under conditions favoring amide linkage formation. The protecting group
15 is then removed and the next protected amino acid residue added. The cycle is repeated until the desired protein has been generated.

The synthetically produced PDGF molecule will have a primary structure substantially homologous and
20 functionally equivalent to those amino acid sequences depicted in Figures 1, 2, or 3. Once synthesized, the PDGF molecule can be glycosylated by the addition of oligosaccharide units to appropriate glycosylation sites in a reaction as described above. Alternatively, Arg,
25 Ser or Thr amino acid residues, already derivatized with the appropriate sugar, can be used directly in the synthesis of the PDGF molecule.

6. Use and Administration of Hyperglycosylated PDGF

30 Hyperglycosylated PDGF prepared according to the invention is generally applied topically to wounds such as cutaneous, dermal, mucosal, or epithelial wounds in vertebrates, particularly mammals including man, domestic and farm animals, sports animals and pets. It
35 may be used to treat any type of full or partial

thickness wounds (burns), radiation wounds, and ulcers such as decubiti and cutaneous ulcers caused by vascular, hematologic and metabolic diseases, infections, or neoplasms.

5 The PDGF may be formulated using available excipients and carriers in the form of a lotion, spray, gel, ointment or as a controlled- or sustained-release dosage form. Additional ingredients such as other growth factors (FGF, CTAP-III, EGF, IGF-1, IGF-2, TGF- β , TGF- α), buffers, local anesthetics, antibiotics, gelling
10 agents, and the like may be included in the formulation.

 For topical administration, which is the most appropriate with regard to cutaneous lesions, standard topical formulations are employed using, for example,
15 0.01-10% concentrations of PDGF. The concentration of formulation depends, of course, on the severity of the wound and nature of the subject. In some treatment regimens, the dose is lowered with time to lessen likelihood of scarring.

20 Controlled- or sustained-release formulations of hyperglycosylated PDGF are made by incorporating the PDGF in carriers or vehicles such as liposomes, nonresorbable impermeable polymers such as ethylene-vinyl acetate copolymers and Hytrel® copolymers,
25 swellable polymers such as hydrogels, or resorbable polymers such as collagen and certain polyacids or polyesters such as those used to make resorbable sutures to provide for sustained release of the PDGF to the wound site over an extended time period, typically from one day
30 to one week. Such incorporation may be particularly desirable when the PDGF is incorporated into a wound dressing. The mechanism of PDGF release from the formulations may be diffusion, osmosis, leaching, dissolution, erosion, or combinations thereof. In
35 diffusional sustained-release formulations, the PDGF

dissolves in and diffuses through the carrier or vehicle on which it is encapsulated/dispersed. In leaching or dissolution formulations, the PDGF is leached from the carrier by body fluids. The concentration of polypeptide in the sustained-release formulation will normally be at least 1 $\mu\text{g/ml}$, usually between 10 $\mu\text{g/ml}$ and 10 mg/ml . In some instances it may be desirable to continually maintain the treatment composition at the affected area or wound site during the healing period. This may be achieved via a multiplicity of intermittent applications of the treatment composition, or by administering the PDGF via a sustained-release dosage form such as those described above. In this regard, the term "continually" denotes true continuous administration such as is achieved by such sustained-release dosage forms or that achieved by such repeated applications that provide a pharmacokinetic pattern that mimics that achieved by true continuous administration.

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples, which are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

25

Deposits of Strains Useful in Practicing the Invention

A deposit of biologically pure cultures of the following strains were made with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland. The accession number indicated was assigned after successful viability testing, and the requisite fees were paid. Access to said cultures will be available during pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 CFR 1.14 and 35 USC 122. All restriction on

availability of said cultures to the public will be irrevocably removed upon the granting of a patent based upon the application. Moreover, the designated deposits will be maintained for a period of thirty (30) years from the date of deposit, or for five (5) years after the last request for the deposit; or for the enforceable life of the U.S. patent, whichever is longer. Should a culture become nonviable or be inadvertently destroyed, or, in the case of plasmid-containing strains, loose its plasmid, it will be replaced with a viable culture(s) of the same taxonomic description.

	<u>Strain</u>	<u>Deposit Date</u>	<u>ATCC No.</u>
	MB2-1 (pYAGL7PB)	April 19, 1990	20911
15	pSV7D-PDGF A102-B1	April 22, 1987	40320
	pSV7D-PDGF A103-B1	April 22, 1987	40321

C. Experimental

The following examples further describe the isolation of DNA encoding PDGF A-chain and B-chain polypeptides, the expression of that DNA in various hosts to produce biologically active PDGF, and the isolation of hyperglycosylated PDGF.

In the following, "digestion" refers to the enzymatic cleavage of DNA by restriction endonucleases. Restriction endonucleases, commonly referred to as restriction enzymes, are well characterized and commercially available and were used in accordance with the manufacturer's specifications. Digestion with restriction enzymes is frequently followed by treatment with alkaline phosphatase according to the manufacturer's specifications to remove the terminal 5' phosphates, thus preventing self-ligation of a vector having two compatible ends.

"Fill in" refers to the enzymatic process of creating blunt ends by repairing overhanging ends generated by certain restriction enzymes. The repair is a function of DNA polymerase I large fragment (Klenow) and deoxynucleotide triphosphates and is used according to manufacturer's specifications.

Gel isolation of a DNA restriction fragment refers to the recovery of a specific fragment, electrophoretically separated on either an agarose gel or a polyacrylamide gel (depending on size of fragment), by either electroelution or melting and extraction of the gel slice.

All DNA manipulations are done according to standard procedures. See Maniatis et al., Molecular Cloning, Cold Spring Harbor Laboratories, 1982. All enzymes used are obtained from commercial sources and used according to the manufacturer's specifications.

1. Isolation and Characterization of PDGF A- and B-Chain cDNA

A lambda-gt10 cDNA library was constructed from poly (A)⁺ RNA from the human clonal glioma cell line U-343 (MGaCl2:6 using the LiCl/urea method modified as described by Betsholtz, C., et al., Cell (1984) 39:447-457. Oligo(dT)-primed synthesis of ds cDNA was performed according to Gubler, U., and Hoffman, B.J., Gene (1983) 25:263-299. The resulting cDNA was treated with T4 DNA polymerase and subcloned into EcoRI-cleaved lambda-gt10 using EcoRI linkers. The recombinant phage were plated in E. coli C600hfl.

Two oligonucleotide probes, designated PDGF A-1 and PDGF A-2, were synthesized based on the known partial amino acid sequence of PDGF A-chain. Both were made using solid-phase phosphoramidite methodology. The double-stranded probe PDGF A-1 was synthesized as two

overlapping 50-bp oligonucleotides and radiolabeled using [α - 32 P]-deoxynucleoside triphosphates and Klenow fragment of DNA polymerase I. PDGF A-2 was synthesized as a 37-base template and a 12-base complementary primer and was
5 radiolabeled as PDGF A-1. The nucleotide sequences (single strand) of the two probes are given below.

PDGF A-1 (86-mer)

CCATCGAGGAGGCCGTGCCTGCAGTGTGC
10 AAGAACCCGCACCGTGATCTATGAAGATCCCCCGCTCC
CAGGTCGACCCACCTCCGCC

PDGF A-2 (37-mer)

AAGCGCTGCACCGGCTGCTGCAACACCAGCAGCGTGA
15

These probes were used to screen the library (2 x 10⁶ clones). Duplicate nitrocellulose filter lifts were hybridized with the probes at 42°C in 20% formamide, 5 x SSC, 50 mM sodium phosphate pH 7.0, 5 x Denhardt's,
20 0.10% SDS, 200 µg/ml sonicated salmon sperm DNA and washed in 0.5 x SSC, 0.1% SDS at 42°C. Clones 13-1 and D1 were selected from among those that hybridized to both probes and sequenced by dideoxy nucleotide chain
25 Partial nucleotide sequences of 13-1 and D1 are shown in Figures 4 and 5, respectively.

The longest open reading frame of D1 predicts a PDGF A-chain precursor of 211 amino acids (shown in Figure 5); the boxed portion designates the 125-amino
30 acid PDGF A-chain polypeptide.

The deduced amino acid sequence of Figure 5 matches the reported partial sequence of the PDGF A-chain obtained by amino acid sequencing except at amino acids
35 119, 141, 143, found to be Ile, Gln, and Ser,

respectively, instead of the previously assigned Val, Arg, and Thr. The ATG codon at amino acid position 1 precedes a basic amino acid (Arg) followed by 18 hydrophobic residues. This is characteristic of a signal peptide sequence and is consistent with the observation that PDGF A-chain homodimers produced by human osteosarcoma cells are secreted. Comparison with preferred signal peptidase cleavage sites suggests that processing may occur between amino acids Ala20 and Glu21. The N-terminal sequence of platelet PDGF A-chain is found at amino acid 87, indicating that a propeptide of 66 amino acids (44% charged residue) is cleaved from the precursor to generate a 125-amino acid A-chain protein. This cleavage occurs after a run of four basic amino acids, Arg-Arg-Lys-Arg. Additional proteolytic processing may occur in the C-terminal region.

The corresponding open reading frame of 13-1 (Figure 4) predicts a PDGF A-chain precursor of 196 amino acids identical in sequence to the precursor of D1 but lacking 15 C-terminal residues. Again, the mature polypeptide is boxed in Figure 4.

cDNA for PDGF B-chain was isolated from the same cDNA library for use in the following experiments in which D1, 13-1, and B-chain cDNA were cloned in an analogous manner, except where indicated.

2. Yeast Expression

Due to the ability of yeast to secrete and process proteins, the genes for the mature PDGF A-chains and B-chain were fused with the sequence of the α -factor leader, a yeast secretory signal sequence which would allow for secretion of PDGF. Yeast transformed with these plasmids would be expected to synthesize a protein containing an NH₂-terminal α -factor leader and COOH-terminal PDGF chain separated by Lys-Arg. Since this

molecule is targeted for secretion, cleavage after the processing site Lys-Arg by the yeast should result in secretion of the mature growth factor. Lys-Arg is the processing site used by the natural prepro-PDGF, as well as the prepro- α -factor.

2.1. Regulatable Secretion in Yeast

PDGF B-chain protein, and the two forms of the A-chain protein, D1 and 13-1, were produced and secreted by yeast strain Saccharomyces cerevisiae AB110 (Mata, ura 3-52, leu 2-04, or both leu 2-3 and leu 2-112, pep 4-3, his 4,580, cir^o) transformed with yeast expression plasmids pYpA6 and pYpA134, respectively. Additionally, PDGF B-chain protein was produced in S. cerevisiae MB2-1 (Mata, uradelta3, leu 2-3, leu 2-112, his 3-11, his 3-15, pep 4delta, cir^o) transformed with yeast expression plasmid pYAGL7PB. The plasmids contain the sequence coding for their respective mature PDGF protein along with pBR322 sequences including the origin of replication and the ampicillin resistance gene, as well as yeast sequences including the 2-micron and selectable markers leu and ura genes. Expression of the mature PDGF genes is inducible and under the control of the regulatable promoter ADH2-glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and α -factor terminator (see section 2.1.4). The individual plasmids are described in more detail below.

2.1.1. Construction of pYAGL7PB: A Yeast Expression Vector for Hyperglycosylated PDGF B-Chain

Plasmid pYAGL7PB is a yeast expression vector which contains an "expression cassette" for PDGF B-chain cloned into the BamHI site of vector pAB24 (described more fully below). Vector pAB24 contains PBR322 and yeast 2 micron sequences including the E. coli amp^R and yeast leu2 and ura3 genes.

The "expression cassette" consists of the following sequences fused together in this order (5' to 3'): ADH2 regulatory sequences, GAP promoter, truncated α -factor leader (EPA no. 324274), PDGF B synthetic gene, and α -factor terminator. The map of plasmid pYAGL7PB is shown in Figure 6. The PDGF B gene cloned into the expression cassette was chemically synthesized employing yeast preferred codons using the phosphoramidite procedure as described by Urdea, et al., (Proc Natl Acad Sci USA (1983) 80:7461) and according to the Dayhoff protein data bank amino acid sequences for the B-chain of PDGF. The PDGF B gene comprises a 327 bp DNA fragment coding for 109 amino acids. The sequence is shown in Figure 3.

2.1.2. Construction of pYpA6 and pYpA134: Yeast Expression Vectors for PDGF A-Chain

In vitro mutagenesis was used to generate XbaI and SalI sites at the end of the two different mature PDGF A-chain genes in order to clone the genes into pAG (see section 2.1.4). In vitro mutagenesis was performed according to the procedure of Zoller and Smith, DNA (1984) 3(6):479-488. A SacI-HindIII fragment, containing the entire coding region for the mature polypeptide, was cloned from each of the PDGF A-chain genes into M13mp19 in order to generate single-stranded template. The following synthetic oligonucleotides were used as mutagenic primers.

<u>Mutation</u>	<u>Sequence of Primer</u>
1. <u>Xba</u> I site at 5' end of 13-1 and D1	CTGCCCATTCTAGATAAGAGAAGCATC
2. <u>Sal</u> I site at 3' end of clone D1	CCCACCTAAAGTCGACTTCCAGATGTGAGG
3. <u>Sal</u> I site at 3' end of clone 13-1	GATGACCCGTCGACCAATCCTGGGA

Mutagenesis of clone D1 was carried out using
 primers 1 and 2; primers 1 and 3 were used for clone
 13-1. An approximately 400-bp XbaI-SalI (partial)
 fragment from clone D1 and an approximately 360-bp XbaI-
SalI (partial) fragment from clone 13-1 were each
 isolated and cloned into pAG, which was digested with the
XbaI and SalI and gel isolated, to give pAG-AD1 and pAG-
 A13.1, respectively. The expression cassettes containing
 the two forms of the mature PDGF A-chain gene were cut
 out as BamHI fragments and each cloned into pAB24,
 previously digested with BamHI and treated with alkaline
 phosphatase, to give plasmids pYpA6 and pYpA134, depicted
 in Figures 7 and 8, respectively.

2.1.3. Yeast Transformation and Expression

Yeast expression plasmids pYpA6 and pYpA134
 were transformed into yeast strain S. cerevisiae AB110
 (Mata, ura 3-52, leu 2-04, or both leu 2-3 and leu 2-
112, pep 4-3, his 4-580, cir^o), as described by Hinnen et
 al. (Proc Natl Acad Sci USA (1978) 75:1929-1933). Yeast
 expression plasmid pYAGL7PB was transformed into yeast
 strain S. cerevisiae MB2-1 (Mata, Ura 3delta, leu 2-3,
leu 2-112, his 3-11, his-315, pep 4delta, cir^o). Yeast
 was plated on ura⁻, 8% glucose, sorbitol plates.
 Transformants were grown in leu⁻, 8% glucose liquid
 medium for 24 hr and then plated onto leu⁻, 8% glucose

sorbitol plates to get individual colonies. Individual colonies were picked and grown in 3 ml of leu⁻, 8% glucose medium for 24 hr at 30°C, and then inoculated (1:50) into 1 liter of ura⁻, 1% glucose media and grown for 75 hr at 30°C. Yeast culture medium was assayed for PDGF activity by the human foreskin fibroblast mitogen assay (see section 5). The yeast transformant pYpA6-NT1 secretes PDGF A-chain (D1 form) into the medium at a level of 750 ng/ml and transformant pYpA134-NT1 secretes PDGF A-chain (13-1 form) into the medium at a level of 325 ng/ml.

For large scale production of hyperglycosylated PDGF B-B homodimer, the procedure was as follows.

2.1.3.1. Preparation of Master/Working Seed Stock
S. cerevisiae MB2-1 (pYAGL7PB) was first streaked onto ura- selective plates and then single transformants or a frozen glycerol stock was individually inoculated into leu- selective medium. After 48 hours of growth, at 30 degrees C, a portion of this culture was frozen in a final volume of about 19% glycerol and frozen in a dry ice/ ethanol bath and stored at -70°C or colder. The other portion, used for expression testing, was grown for about 72 hours in a medium similar to ura- selective medium-2 (see below), with the exception that the glucose level in the medium was 1% instead 8%. This was agitated for 72 hours, at 30 degrees C. The cultures were harvested, and cell free supernatants were prepared and assayed for PDGF B expression levels. Aliquots from the culture exhibiting the highest expression level were selected as the seed stock.

2.1.3.2. Inoculum 1

A seed stock aliquot, prepared in section 2.1.3.1., was thawed and one aliquot used to inoculate 500 ml of ura- selective medium-1 in a shake flask. This culture was incubated for 1 to 2 days at a controlled temperature with agitation. Inoculum 1 may consist of one to three 500 ml cultures. The inoculum was used immediately to inoculate complete media in 16 L seed fermentors. Alternatively, the inoculum was stored at 2-8°C for up to seven days, prior to use.

2.1.3.3. Inoculum 2

Each 500 ml culture of inoculum 1 was used to inoculate ura- selective medium-2 in a 16 L seed fermentor. The inoculum 2 was grown for about 18 hours, at 30 degrees C, at an airflow rate of 10 LPM and an agitation rate of 400 RPM, back pressure was one to three psi. This was used to inoculate production medium in a large scale fermentor. Inoculation ratios varied depending on scale of production fermentor used (sizes varied from 3,400 L to 10,000 L). One to three 16 L seed fermentors were typically used to set a production fermentor. The complete media contained salts, vitamins, trace elements, casamino acids and glucose.

2.1.3.4. Fermentor Culture

The inoculum 2 was used to inoculate complete production medium in a large scale production fermentor of 3,400 L, 4,000 L, and/or 10,000 L capacity. This culture was incubated with controlled temperature, aeration, and agitation for about 72 hours. Harvest time was determined by fermentation time alone.

2.1.3.5. Media Used in Large Scale Production

The components of the various media used above were as follows.

5	<u>Ura- Selective Medium</u>		
	Ura-/Sorbitol media	485	ml
	20% Casamino Acids	12.5	ml
	1% Tryptophan	2.5	ml
	1% Adenine	2.5	ml
10	50% Glucose	80	ml
	<u>Ura-/Sorbitol Medium</u>		
	Agar	80	g
	Yeast Nitrogen Base w/o Amino Acids	26.8	g
15	Sorbitol	728	g
	Milli-Q Water	3.6	L
	<u>Leu- Selective Medium</u>		
	10X Basal Salts w/o Amino Acids	100	ml
20	50% Glucose	160	ml
	Leu- Supplements	100	ml
	5% Threonine	4	ml
	Pantothenate/Inositol Solution q.s. with Milli-Q Water to 1L	2.5	ml
25	<u>Leu- Supplements</u>		
	Adenine	4	g
	Uridine	3	g
	Tryptophan	2	g
	Histidine	2	g
30	Arginine	2	g
	Methionine	2	g
	Tyrosine	3	g
	Lysine	3	g
35	Phenylalanine	5	g

10X Basal Salts

	Yeast Nitrogen Base w/o Amino Acids	267.2 g
	Succinic Acid	400 g
5	Sodium Hydroxide	240 g
	q.s. with Milli-Q water to 4L	

Pantothenate/Inositol Solution

	D-Pantothenic Acid Hemicalcium Salt (1.2%)	12.0 g
10	Myoinositol (1.2%)	12.0 g
	q.s. with Milli-Q water to 4 L	

Ura- Selective Medium-1

	Basal Salts (10X) w/o Amino Acids	100 ml
	50% Glucose	160 ml
15	20% Casamino Acids	25 ml
	(Sheffield Co. or Marcor)	
	1% Adenine	5 ml
	1% Tryptophan	5 ml
	Pantothenate/Inositol Solution	2.5 ml
20	q.s. to 1 L using MILLI-Q water and filter through 0.2 μ m filter units	

Ura- Selective Medium-2

25	Yeast Nitrogen Base w/o Amino Acids	100 g
	Casamino Acids	200 g
	Ca D-Pantothenate	500 mg
	Myo-Inositol	500 mg
	Glucose, 50%	1600 ml
	Antifoam (SAG-471)	1.0 ml
30	Milli-Q water	9 L
	Inoculum 1	480 ml
	PDGF B	
	pH to 5.6-5.8 using 75% Phosphoric Acid or 50% NaOH.	

Complete Production Medium

	Casamino Acids	70 kg
	Ammonium Sulfate	17.5 kg
	$(\text{NH}_4)_2\text{SO}_4$	
5	Monopotassium Phosphate	3.5 kg
	KH_2PO_4	
	Magnesium Sulfate (Epsom salts)	1.75 kg
	$\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$	
	Sodium Chloride, NaCl	350 g
10	Calcium Chloride, Anhydrous, CaCl_2	350 g
	3400 L trace elements powder (T-24)	1 container
	Antifoam (SAG 471)	28 fl. oz.
	Dextrose (Cerelease 2001) (batch)	123 kg (batch)
	3400 L vitamin powder (T-24)	1 container
15	P-10 water (Manteca) (batch)	815 gallons
	Inoculum 2	22 L
	pH to 6.0.	
	<u>3400 L Trace Elements</u>	
20	Boric Acid	5.0 g
	Cupric Sulfate	0.4 g
	Potassium Iodide	1.0 g
	Ferric Chloride	2.0 g
	Manganous Sulfate Monohydrate	3.9 g
25	Sodium Molybdate	2.0 g
	Zinc Sulfate	3.9 g

30

35

3400 L Vitamin Powder

	Thiamine	9.5 g
	Pyridoxine	9.5 g
	Biotin	0.6 g
5	p-aminobenzoic acid	6.3 g
	Riboflavin	6.3 g
	Folic Acid	0.6 g
	Niacin	9.5 g
	Myo-Inositol	115 g
10	Ca Pantothenate	115 g

2.1.4. Plasmids Used for the Preparation of Yeast
Expression Vectors

15 pAG- is a general yeast expression cassette
vector derived from pAG-TNF where pAG-TNF is only used
for convenience of cloning with the pAG- construct being
relevant to this application.

20 The expression cassette vector, pAG-TNF,
contains the regulatable ADH2-GAPDH promoter, the α -
factor leader, the synthetic TNF gene, and the α -factor
terminator cloned in pBRdeltaRI-Sal. The ADH2-GAPDH
promoter was isolated as a 1.0-Kbp BamHI-NcoI fragment
from pAGdeltaXbaGAP1. The 5' end of the α -factor leader
was supplied as a synthetic adaptor for the following
25 sequence and having NcoI- and PstI-compatible overhangs:

CATGAGATTCCTTCAATTTTACTGCA
TCTAAGGAAGTTAAAAATG

30 The 3' end of the α -factor leader, the synthetic TNF gene
and the α -factor terminator was isolated as a PstI-BamHI
fragment from pHG100-TNF. The three fragments were
ligated together and cloned into pBRdeltaRI-Sal which had
been previously digested with BamHI and treated with
35 alkaline phosphatase.

pBRdeltaRI-Sal was constructed by digesting pBR322 with EcoRI and SalI, filling in the overhangs with Klenow fragment, and ligating on BamHI linkers. The vector and linkers were digested with BamHI and the

5 BamHI-BamHI 3.8 kb vector was gel isolated and recircularized by self-ligation. The resulting plasmid was designated pBRdeltaRI-Sal.

The plasmid pAGdeltaXbaGAP1 contains the ADH2-GAPDH hybrid promoter and the GAPDH terminator cloned

10 into pBRdeltaRI-Sal. The ADH2-GAPDH promoter (the only sequence pertinent to this application) was isolated as a 1.1-kb BamHI-NcoI fragment from pJS103 (described below). In addition, an approximately 90-bp XbaI-XbaI deletion was introduced into the 5' end of the promoter fragment

15 by cutting the plasmid with XbaI, filling in the overhang ends with Klenow fragment, and dNTPs and recircularizing the plasmid, thus giving pAGdeltaXbaGAP1.

pHG100-TNF contains the α -factor promoter, leader, and terminator with the synthetic gene coding for

20 TNF inserted in frame at the 3' end of the leader. The 1.0 kb Pst-BamHI fragment isolated from this plasmid contains 240 bp of the 3' end of the α -factor leader, the 494-bp synthetic TNF gene (as an XbaI-SalI fragment) and the 272-bp α -factor terminator. The α -factor sequences

25 which are the only sequences relevant to this application are derived from pAB114. pAB114 is described in EPO 0 116 201, pages 14-18, and Brake, A.J., et al., Proc Natl Acad Sci USA (1984), 81:4642-4646. The only difference is that a silent mutation was introduced by

30 M13 mutagenesis to create an XbaI site at the 3' end of the leader to facilitate cloning of heterologous genes.

The comparison of the 3' end of the α -factor leader from the wild type (pAB114) versus the altered α -factor (pHG100) illustrated below shows that a silent

35 mutation was incorporated to code for an XbaI site just

5' to the processing site (Lys-Arg). This allows for insertion of heterologous genes without the "spacer" codons (must provide the Lys-Arg processing site and maintain reading frame).

5

10

15

20

25

30

35

pJS103

Plasmid pJS103 contains the inducible hybrid ADH2-GAPDH promoter. The hybrid promoter is made up of the transcriptional and translational initiation region from the GAPDH promoter and is under the regulatory control of the ADH2 transcriptional regulatory region. The ADH2 transcriptional regulatory region is derepressed in the absence of a readily available source such as glucose (without exogenous inducer). By allowing for glucose exhaustion after the yeast culture is grown to high density, the transcriptional control region will be derepressed and expression of the desired peptide will occur.

Plasmid pJS103 was constructed as follows. The ADH2 portion of the promoter was constructed by cutting a plasmid containing the wild-type ADH2 gene from plasmid pADR2 (Beier et al., Nature (1982) 300:724-728) with restriction enzyme EcoRV, which acts at position +66 relative to the ATG start codon, as well as in two other sites in pADR2, outside of the ADH2 region. The resulting mixture of a vector fragment and two smaller fragments was resected with Bal31 exonuclease to remove about 300 bp. Synthetic XhoI linkers were ligated onto the Bal31-treated DNA. The resulting DNA linker vector fragment (about 5 kb) was separated from the linkers by column chromatography, cut with restriction enzyme XhoI, religated, and used to transform E. coli to ampicillin resistance. The positions of the XhoI linker were determined by DNA sequencing. One plasmid which contained an XhoI linker within the 5' nontranscribed region of the ADH2 gene (position -232 from ATG) was cut with the restriction enzyme XhoI, treated with nuclease S1, and subsequently treated with the restriction enzyme EcoRI to create a linear vector molecule having one blunt end at the site of the XhoI linker and an EcoRI end. The

GAP portion of the promoter was constructed by cutting plasmid pPGAP1 with the enzymes BamHI and EcoRI, followed by the isolation of the 0.4 Kbp DNA fragment. This purified fragment was then completely digested with the enzyme AluI and an approximately 200 bp fragment was isolated.

This GAP promoter fragment was ligated to the ADH2 fragment present on the linear vector described above to give plasmid pJS103.

pPGAP1

pPGAP1 is a yeast expression cassette vector which has a polyrestriction site linker between the GAPDH terminator and a truncated GAPDH promoter region. The polyrestriction site contains the recognition sites for NcoI, EcoI, and SalI, and the cassette is excisable as a BamHI fragment. The preparation of pPGAP1 is described in EPO 164556 and Travis, J., et al., J Biol Chem (1985) 260(7):4384-4389. In both references pPGAP1 is referred to pPGAP.

pAB24

Plasmid pAB24 (Fig. 9) is a yeast shuttle vector which contains the complete 2 μ sequence (Broach, Molecular Biology of the Yeast Saccharomyces (1981) Vol. 1, p. 445, Cold Spring Harbor Press) and pBR322 sequences. It also contains the yeast Ura 3 gene derived from plasmid YEp24 (Bostein et al., Gene (1979) 8:17) and the yeast LEU^{2d} gene derived from plasmid pCl/1. EPO Publ. No. 116,201. Plasmid pAB24 was constructed by digesting YEp24 with EcoRI and religating the vector to remove the partial 2 μ sequences. The resulting plasmid, YEp24deltaRI, was linearized by digestion with ClaI and ligated with the complete 2 μ plasmid which had been linearized with ClaI. The resulting plasmid, pCBou, was

then digested with XbaI and the 8605 bp vector fragment was gel isolated. This isolated XbaI fragment containing the LEU²d gene isolated from pCl/1; the orientation of the LEU²d gene is in the same direction as the URA3 gene.

5 Insertion of the expression cassette was in the unique BamHI site of the pBR322 sequences, this interrupting the gene for bacterial resistance to tetracycline.

3. Mammalian Cell Expression

10 In order to establish a permanent cell line producing PDGF, the entire cDNA was cloned into a mammalian cell expression vector which contains a transcriptional regulatory element, a polyadenylation site, and a transcriptional terminator signal. The

15 resulting plasmid along with a selectable marker was introduced into Chinese hamster ovary cells (CHO).

3.1 Constructions of Mammalian Cell Expression Vectors pSV7d-PDGF-A102, pSV7d-PDGF-A103, and pSV7d-PDGF-B1

20 Three separate mammalian cell expression vectors were constructed by isolating EcoRI fragments from each of the three cDNA clones and ligating them into pSV7d (see §3.4 below) previously digested with EcoRI and treated with alkaline phosphatase. The resulting clones

25 pSV7d-PDGF-A103 (DdDDD1), pSV7d-PDGF-A102 (13-1), and pSV7d-PDGF-B1 (B chain) were isolated and characterized by restriction digests. These plasmids were used to produce the chimeric plasmids pSV7d-PDGF-A102-B1 and pSV7d-PDGF-A103-b1 for coexpression of B chain and A

30 chain. Large-scale plasmid preparations were carried out for all of the constructions described. The DNA was used to transfect CHO cells.

3.2 CHO Cell Transfections

Transfections were performed as follows:

CHO dhfr⁻ cells (Urlaub and Chasin, Proc Natl Acad Sci (USA) (1980) 77:4216) were plated at a density of 5 x 10⁵ to 10⁶ cells per 10-cm dish prior to transfection in nutrient medium (F12 supplemented with 1.18 mg/ml Na₂CO₃, 292 µg/ml glutamine, 110 µg/ml sodium pyruvate, 100 U/ml penicillin, 100 U/ml streptomycin, 200 µg/ml proline, and 10% FCS). The CHO cells were transfected with each of the pSV7d-PDGF expression plasmids that were mixed with plasmid pAD-dhfr, which bears a selectable marker (a dhfr gene driven by the adenovirus major late promoter, see below), using a modification of the procedure described by Graham and van der Eb, Virology (1973) 52:456-467. The samples, containing a total of 10 µg of plasmid DNA, were added to the dishes and allowed to settle onto the cells in a carbon dioxide incubator (37°C). Six hours later, the supernatants were aspirated, the cells rinsed gently with Ca- and Mg-free phosphate-buffered saline (PBS-CMF), and the dishes exposed to 15% glycerol as an adjuvant for 3.5-4 min. The cells were then rinsed gently and fed with the above-described medium.

Forty-eight hours after the addition of DNA to the cells, the cells were split 1:20 into selective medium (DMEM supplemented with a 1:1 mixture of fetal calf serum and dialyzed fetal calf serum in addition to the components described above). After growth in selective medium for 1-2 weeks, colonies appeared and were isolated and grown individually. Assays for PDGF were performed on each of the clones (as described below).

Transfections in which pSV7d-PDGF-A103 plus pSV7d-PDGF-B1 and pSV7d-PDGF-A102 plus pSV7d-PDGF-B1 are coprecipitated were also performed in addition to

transfections with the chimeric plasmids described in §3.1 in order to establish cell lines that are producing PDGF as a heterodimer of A-chain and B-chain.

The plasmid pAD-dhfr, bearing the mouse
5 dihydrofolate reductase (dhfr) gene was constructed by fusing the major late promoter from adenovirus-2 (Ad-MLP, map units 16-17.3) to the mouse dhfr cDNA (Subramani et al., J Mol Cell Biol (1982) 1:584-864) at the 5' end. DNA coding for the intron for SV40 small t antigen and
10 the SV40 early region polyadenylation site was obtained from pSV2-neo (Southern and Berg, J Mol Appl Genet (1982) 1:327-341), and fused to the 3' end of the dhfr cDNA. These three segments were subclones into pBR322 to obtain the plasmid pAD-dhfr.

15 Several of the primary CHO transfected cell lines secreted PDGF into the medium at levels of 1-2 ng/ml/24hr as determined by the mitogen assay described in §5.

Several primary clones from each of the
20 transfected lines were selected for amplification in increasing amounts of methotrexate, 0.05 and 0.1, and 1.0 μ M concentrations. Amplification and selection of methotrexate-resistant colonies were performed according to Kaufman, R.S., and Sharp, P.A., J Mol Biol (1982)
25 159:601-621.

3.3 Results of PDGF Expression

Results of PDGF expression from CHO cells are summarized in Table 1 below. Media from CHO cell lines
30 transfected with PDGF expression plasmids were assayed by the PDGF mitogen assay described in §5. The results of these experiments indicate that the PDGF A-chain homodimer is active.

Table 1

CHO Cells Transfected with PDGF Expression Plasmids:
Level of Active PDGF Secreted into Media

5 EXPERIMENT 1

<u>Cell Lines</u>	<u>Plasmid</u>	<u>Level of PDGF/24 hr</u>
Primary Cell Lines	pSV7d-PDGF-A102	1-2 ng/ml
	pSV7d-PDGF-A103	no cells survived
	pSV7d-PDGF-B1	1-2 ng/ml
10 Amplified cell lines methotrexate level: 0.1 μ M	pSV7d-PDGF-A102	50-100 ng/ml
	pSV7d-PDGF-B1	100-150 ng/ml
15 Methotrexate level: 1 μ M	pSV7d-PDGF-A102	50-100 ng/ml
	pSV7d-PDGF-B1	100-150 ng/ml

EXPERIMENT 2

20	Primary Cell Lines	pSV7d-PDGF-A102	10-20 ng/ml
		pSV7d-PDGF-A103	1-2 ng/ml
		pSV7d-PDGF-B1	10-20 ng/ml
		pSV7d-PDGF-A102	1-2 ng/ml
		+ pSV7d-PDGF-B1	
		pSV7D-PDGF-A103	1-2 ng/ml
		+ pSV7d-PDGF-B1	

Amplified Cell lines

25	methotrexate level: 1 μ M & 2 μ M	No increase in level of PDGF secreted into media.
----	----------------------------------------------	------------------------------------------------------

EXPERIMENT 3

30	Primary Cell Lines	pSV7D-PDGF A102-B1	40 ng/ml
		pSV7D-PDGF A103-B1	no secretion detected

35

3.4 Construction of pSV7d

The mammalian cell shuttle vector plasmid pSV7d contains the SV40 origin of replication and early promoter (315 bp, PvuII pos 272-StuI pos 5193 with an 8 bp deletion between nucleotides 173 and 182), a polylinker, and the SV40 poly A addition site (217 bp, BclI pos 2775-pos 2558). Buchman, L., et al., "The SV40 Nucleotide Sequence," pp. 7799-841, DNA TUMOR VIRUSES, Second Edition, edited by Tooze, J. The sequence of the SV40 region is shown in Figure 13. The SV40 sequences were cloned into the pBR322 derivative pML (Lusky and Botchan, Cell (1984) 36:391) between nucleotide 4210 and NruI pos 973. Maniatis, T., et al., "Nucleotide Sequence of pBR322," (1983) Molecular Cloning: A Laboratory Manual. The SV40 sequences are positioned such that the direction of transcription from the early promoter is in the same direction as the ampicillin gene of the vector. A map of the plasmid is shown in Figure 14.

20 4. Isolation of Hyperglycosylated PDGF Expressed in Yeast

PDGF B-B homodimer produced in S. cerevisiae MB2-1, as described above, exists in a heterogenous state with respect to glycosylation. That is, upon further separation, at least two PDGF forms can be distinguished--one being highly glycosylated and the other form having little or no carbohydrate moieties attached. The more highly glycosylated fraction is dramatically more active as determined by the mitogenic assay described in §5.2, below. PDGF B-B homodimer was purified and the hyperglycosylated fraction isolated as follows.

4.1. Purification of PDGF B-B from *S. cerevisiae* MB2-1

Hyperglycosylated PDGF was recovered from *S. cerevisiae* MB2-1 as follows. Cells were separated from the supernatant using a Westphalia continuous flow through centrifuge. The cells were treated and discarded and the supernatant was recovered and stored chilled to await filtration. The supernatant was then passed through a 100k ultrafilter. The permeate was collected and stored chilled.

Ion-exchange chromatography was performed to recover and concentrate PDGF from the filtered supernatant. The supernatant was adsorbed to an AMF Zeta Prep SP 3000 or 32L ion-exchange cartridge under conditions where PDGF binds to the resin. The cartridge was washed with buffer and equilibrated with 0.02M acetic acid. The equilibrated cartridge was loaded with the 100K permeate. The cartridge containing the bound PDGF may be stored up to 72 hours at 2-8°C after loading.

To elute the bound PDGF, the cartridge was first washed with 0.05M acetic acid/0.5M sodium chloride to remove contaminant proteins. The optical density was monitored at 254 nm. Elution of PDGF B-B occurs with 0.05M sodium phosphate/1M sodium chloride, pH 7.5. All major peaks as determined by monitoring OD₂₅₄ were collected and analyzed for PDGF B content by analytical Reverse Phase HPLC (RP HPLC). All eluate peaks containing substantial amounts of PDGF B were pooled. The purity of the eluted fractions at this step ranged from 40% to 80%. The pooled eluates may be stored up to 72 hours at 2-8°C before further processing.

The pooled SP cartridge eluate was titrated to pH 8 with 6N hydrochloric acid or 6N sodium hydroxide as needed. A copper chelate sepharose column was charged with Cu⁺⁺ by the application of 0.1 M copper sulfate.

The column was then washed thoroughly with 10% acetic acid/1M sodium chloride. The prepared load was pumped onto the column which had been equilibrated with 0.05M sodium acetate/1M sodium chloride, pH 8. The eluate was
5 monitored at 254 nm. The loaded column underwent a series of washes beginning with 0.05M sodium acetate/1M sodium chloride, pH 8. The next wash consisted of 0.05M sodium acetate/ 0.05M sodium chloride, pH 8. The third
10 wash titrated the column to pH 5 with 0.05M sodium acetate/0.05M sodium chloride, pH 5. The elution buffer was 0.05M sodium acetate/0.5M sodium chloride, pH 5. Fractions of the eluate peak were collected and analyzed for PDGF B content and purity by RP HPLC. Purity of the
15 pooled fractions at this step ranged from 54% to 90%. The pool may be stored up to 72 hours at 2-8°C prior to further processing.

The pooled copper chelate eluate was concentrated and diafiltered using a 10K ultrafilter to eliminate excess salt and Cu^{++} . Once the volume had been
20 reduced and the PDGF B concentration was between 2 to 5 mg/ml, the retentate was diafiltered with purified water until the conductivity level measured in the permeate was less than 0.1 mS/cm (10 to 20 retentate volumes).

25 The PDGF B fraction from above was then subjected to sulfopropyl HPLC. The SP column was equilibrated with 0.05M sodium phosphate, monobasic. The starting material was titrated to pH 4.2 using phosphoric acid. After loading, the column was washed with the
30 equilibration buffer. The column was then washed with 0.05M sodium phosphate, pH 7. The PDGF B was eluted with a linear gradient of 0 to 1M sodium chloride in 0.05 sodium phosphate over 15 column volumes. Fractions were collected and analyzed by RP HPLC. The pooled SP HPLC

fractions may be stored up to 48 hours at 2-8°C before further processing.

5 The final product was concentrated and diafiltered with purified water (P30) on a 10K AG Technology hollow fiber ultrafilter. The finished bulk product had a concentration of 2 to 5 mg/ml and was free of excess salt. The ultrafiltration circuit consisted of the same components specified in the first ultrafiltration step. The retentate was again diafiltered until the permeate
10 conductivity was less than 0.1 mS/cm. The retentate was then passed through a 0.2 micron filter. The product may be stored lyophilized.

4.2. Isolation of Hyperglycosylated PDGF B-B Homodimer

15 As explained above, the purified PDGF B product from above exists in a heterogeneous state with respect to degree of glycosylation. Lots tested contained from about 50% highly glycosylated PDGF to about 75% highly glycosylated PDGF, as determined by ConA affinity
20 chromatography. Table 2 shows the composition of the heterogeneous mixture recovered in Example 4.1, including the percentage of highly glycosylated and less or nonglycosylated PDGF, as well as the activity of these fractions.

25

30

35

Table 2

Composition of Purified PDGF B
From Example 3.1

Lot #	% Highly glyco. PDGF ²	% less or nonglyco.	Mixture	<u>Percent Activity¹</u>	
				Highly glyco. PDGF	Less or nonglyco.
MEC109	55	45	67	105	48.5
MEC508	50	50	94	84.1	36.5
MEC577	52	58	100	106.5	47
MEC710	54	46	88.5	127.4	35
MEF043	70	30	177	--	--
MEF593	73	27	83	--	--

¹ Activity was determined using the HFF mitogen assay described herein. Numbers were generated based on a PDGF B standard that was assigned 100% activity.

² Fractions were separated using ConA affinity chromatography as described herein.

As can be seen, the less or nonglycosylated fractions were consistently, significantly lower in biological activity than the highly glycosylated fraction, the glycosylated fraction exhibiting as much as three times the activity as the less glycosylated fraction. Figure 10 also shows that as percent glycosylation increases, so does activity.

ConA affinity chromatography was used to separate the glycosylated and less glycosylated fractions from one another as follows. ConA-Sepharose 4B (Pharmacia) was packed into a 15 cm x 1 cm column to a final volume of 13 ml. The lyophilized products from

§4.1 were diluted in water to a concentration of approximately 1 mg/ml and loaded onto the column. After the protein was loaded, the column was washed with equilibration buffer to eliminate any protein which did not bind to the resin. The glycosylated protein was then eluted off the column with 0.4M α -methyl-D-mannopyranoside (sigma) in equilibration buffer. Affinity chromatography with ConA-Sepharose yielded two protein fractions. One did not bind to the resin, and the other was eluted off the column only after treatment with 0.4M α -methyl-D-mannopyranoside. A typical chromatogram is shown in Figure 11.

To determine whether mannose was the carbohydrate present, the uptake of ^3H -mannose by PDGF B-producing cells was measured. Specifically, these cells were grown at 30°C in 25 ml of Leu minus media containing 8% glucose for 48 hours. Two ml of this growth was then transferred to 100-500 ml of Ura minus media with 1% glucose. At 43 hours, 150-840 μCi of D-[2,6- ^3H]-mannose (Amersham) was added to the media and the growth was continued. The cells were harvested at 70 hours by centrifugation at 5000 g for 20 minutes at 4°C. The supernatant was collected and acidified by the addition of glacial acetic acid to a final concentration of 50 mM. Seventy-five μg of nonradioactive PDGF was then added to the supernatant as a carrier. The supernatant was loaded onto a 7 ml S-Sepharose fast flow (Pharmacia) column which had been equilibrated with 50 mM acetic acid/0.12 M NaCl. Following the loading, the column was washed with equilibration buffer followed by a wash with 50 mM acetic acid/0.5 M NaCl. The PDGF was then eluted off the column with 50 mM acetic acid/1.0 M NaCl. Fractions collected during the second wash and the elution were counted to determine if the in vivo

incorporation was successful. A control experiment was also carried out in which the ^3H -mannose was added to the supernatant after centrifugation to determine if there was any nonspecific binding to PDGF. The results
5 indicate that no mannose is associated with PDGF unless it is covalently bound to the molecule.

The in vivo incorporation of D-[2,6- ^3H]-mannose was successful. The results of this experiment, are illustrated in Figure 12. As can be seen, mannose
10 appears to be the carbohydrate which is involved in the glycosylation of PDGF expressed in yeast.

To confirm this, deglycosylation was carried out by treating PDGF with α -mannosidase (Boehringer Mannheim) in a ratio of 10:1. The reaction was carried
15 out in 50 mM Na Acetate/10 mM ZnCl_2 pH 4.0 at 37°C. The reaction was allowed to take place over a period of five days, and was stopped by boiling the solution for 3 minutes. The boiled solution was then passed through a Bio Gel P-10 (BioRad) gel filtration column, equilibrated
20 with 50 mM acetic acid. The PDGF-containing peak was pooled and dialyzed against dH_2O to insure elimination of all free mannose residues. The final product was subjected to analysis by SDS-PAGE, mitogenic assay, and mannose determination by periodate (as explained below).
25

Since PDGF B has a number of potential O-linked glycosylation sites, deglycosylation was also attempted by β -elimination. This was done by suspending PDGF in 0.1 N NaOH and incubating at 37°C for 48 hours. Following incubation, the protein was passed through a
30 Bio Gel P-10 column, equilibrated with 50 mM acetic acid, to desalt and remove any free mannose residues. The PDGF peak was pooled, dialyzed against dH_2O , and tested for biological activity as well as for the presence of mannose by the periodate reaction. The elimination
35

reaction resulted in the removal of counts from the protein, indicating that radioactive mannose had been removed.

The periodate method was used to determine the number of moles of mannose per mole of PDGF in the highly and less glycosylated fractions from Experiment 4.1 as well as in the deglycosylated products above. This method, well known in the art, calls for the oxidation of the sugar by periodate, followed by a colorimetric determination of the residual periodate not utilized during the oxidation process (see Avigad, G., Carbohydrate Research (1969) 11:119-123, the disclosure of which is incorporated herein by reference). Analysis by the periodate reaction showed that the fraction that did not bind to the ConA resin was indeed less glycosylated than the protein which did bind. On the average, the less glycosylated fraction contains from 2-5 moles of mannose/mole of PDGF. The more glycosylated protein had a higher apparent molecular weight, as determined by SDS-PAGE.

Furthermore, deglycosylation with α -mannosidase gave both a decrease in the number of moles of mannose/mole of PDGF as well as in the mitogenic activity. Before treatment with α -mannosidase there were 9 moles of mannose/ mole of PDGF as determined by the periodate method. After the deglycosylation reaction, there were only 6.5 moles of mannose/mole of PDGF. This figure would not be expected to go to zero since the α -mannosidase only cleaves the external mannose residues and not the internal ones. After the reaction, the biological activity went down to approximately 60% of the original activity. These results support the theory that glycosylation plays a role in the biological activity of PDGF. The SDS-PAGE results also show a lower molecular

weight protein following the deglycosylation reaction with α -mannosidase.

After β -elimination, the periodate reaction showed a decrease in moles of mannose from 9 moles to .8-6 moles. The biological activity, however, was destroyed under these harsh conditions.

To determine which amino acid residues are glycosylated when PDGF B is produced in yeast, a heterogenous mixture containing approximately 70% highly glycosylated material was subjected to tryptic digestion and the tryptic fragments weighed and sequenced. Several fragments were heavier than the theoretical molecular weight of the amino acid residues contained therein, the increase in weight being in exact increments of the weight of mannose. Results varied, and it was sometimes difficult to determine which residue was indeed glycosylated since some tryptic fragments contained more than one glycosylation site. However, preliminary experiments indicate that the highly glycosylated PDGF appears to have from 0-2 mannoses on Thr-6, 0-1 on Thr-20, 0-1 on Ser-26, 0-2 on Thr-63, 0-3 on Thr-88, 0-3 on Thr-90, and 0-1 on Thr-101.

This determination was also carried out on a PDGF B heterogeneous mixture having a higher percentage of less glycosylated material than hyperglycosylated PDGF. No sugar groups were found at Thr-20, Ser-26 or Thr-101. Therefore, it is hypothesized that a purified sample of the less glycosylated PDGF B would lack sugars on these residues.

30

35

5. Bioassay for PDGF Activity

5.1. PDGF Produced in Mammalian Cells

Chinese hamster ovary cells (CHO) used in the process were normally grown in medium supplemented with 10% fetal calf serum (FCS). This presented a problem in assaying for PDGF due to the background contributed by the native bovine PDGF in FCS. Thus, it was necessary to devise culture conditions that support production of recombinant products while reducing the background. Using CHO cells transfected with the human β -interferon gene, it was found that expression levels reached approximately 50% of those observed in 10% FCS with culture medium supplemented by 5% platelet-deficient horse plasma (PDHS). This medium, when added to either the cell growth or mitogen assays, gave no background.

CHO transformants were assayed by adding 10 μ l of a 24-hr supernatant harvest in 5% PDHS (and necessary dilutions, usually serial twofold and threefold) to the well of a 96-well plates of the assay.

5.2. PDGF Produced in Yeast

Samples of supernatants of yeast which had expressed PDGF were appropriately diluted, depending upon expected activity, and then serially diluted in DMEM containing 1% bovine serum albumin (BSA). Aliquots (10 μ l) of each dilution were placed in the wells of the assay plates.

5.3 Human Foreskin Fibroblast (HFF) Mitogen Assay for PDGF

HFF stocks were stored frozen; freezing was at passage 13. Prior to use, HFF were thawed, and grown in T75 flasks until confluent, which usually occurred at 5-7

days. Growth medium contained Dulbecco's Modified Eagles Medium (DMEM), 20% fetal bovine serum (FBS), 1 mM sodium pyruvate, 300 µg/ml L-glutamine, 100U/ml penicillin, and 100 µg/ml streptomycin. Cells were incubated at 37°C in humidified 7% CO₂, 93% air atmosphere. At confluency, cells were passaged by rinsing the monolayer with phosphate buffered saline (PBS) lacking Ca⁺⁺ and Mg⁺⁺, dissociating them in trypsin containing EDTA, and diluting them with Growth Medium. Cells were passaged no more than 8 times after thawing.

To assay for PDGF, HFFs were plated as follows. The cells were rinsed and dissociated with trypsin as above. The trypsinized cells were pelleted, and resuspended to a concentration of 1 x 10⁵ cells/ml in medium similar to Growth Medium, except that 5% FBS replaced 20% FBS; 100 µl of suspension was dispensed into each well of a 96 well microtiter plate, and the cells were incubated 5-6 days under the above described conditions.

PDGF in the sample was determined by monitoring ³H-thymidine incorporation into HFF DNA stimulated by PDGF. Samples were added to the wells containing HFF monolayers, and the assay plates incubated as above for 18 hours. The HFF cultures were then pulsed with [Methyl-³H] thymidine (10 µC/ml final concentration, 1 µC/well) at 37°C under the above described incubation conditions for 8 hours. After incubation, the cells were rinsed with PBS and fixed. Fixing was by incubation with 5% trichloroacetic acid (TCA) and then 100% methanol for 15 minutes, followed by drying in air. The cells were then solubilized with 0.3N NaOH, and counted in a liquid scintillation counter.

Control samples were treated as the samples described above, and were prepared as follows. For positive controls used in activity tests of PDGF produced

in S. cerevisiae MB2-1, PDGF B-B homodimer from
S. cerevisiae MB2-1, transformed with pYAGL7PB, was
dissolved to a final concentration of 56 ng/ml in DMEM
containing 1% BSA. A standard curve was prepared; the
5 first point was 5.6 ng/ml, the remaining points were
2-fold serial dilutions. For positive controls in all
other tests, PDGF, purchased from PDGF, Inc., was
dissolved to a final concentration of 100 ng/ml in DMEM
containing 10 mg/ml BSA. A standard curve was prepared;
10 the first point was 10 ng/ml, the remaining points were
2-fold serial dilutions.

Each dilution was tested in triplicate.
Negative controls, in 1:10 dilution of 5% FCS, which
lacked both sample and control PDGF, were also run. As
15 can be seen in Table 2, and explained above,
hyperglycosylated PDGF exhibited far more biological
activity than its less or nonglycosylated counterpart.

Thus, hyperglycosylated PDGF and methods for
isolating the same have been disclosed. Although
20 preferred embodiments of the subject invention have been
described in some detail, it is understood that obvious
variations can be made without departing from the spirit
and the scope of the invention as defined by the appended
claims.

25

30

35

Claims

1. A composition of hyperglycosylated PDGF.
- 5 2. The composition of claim 1 wherein said hyperglycosylated PDGF includes at least an average of 10 moles of carbohydrate per mole of dimer.
- 10 3. The composition of claim 1 wherein said hyperglycosylated PDGF includes at least an average of 17 moles of carbohydrate per mole of dimer.
- 15 4. The composition of claim 2 wherein said hyperglycosylated PDGF comprises PDGF B-B homodimer.
5. The composition of claim 3 wherein said hyperglycosylated PDGF comprises PDGF B-B homodimer.
- 20 6. The composition of claim 4 wherein said carbohydrate comprises mannose.
7. The composition of claim 5 wherein said carbohydrate comprises mannose.
- 25 8. The composition of claim 1 wherein said hyperglycosylated PDGF is produced in yeast.
9. A PDGF B-B homodimer having at least 17 moles of mannose per mole of dimer.
- 30 10. The PDGF of claim 9 wherein said PDGF is produced in yeast.
11. A method of producing hyperglycosylated PDGF comprising:
- 35

(a) providing a mixture containing a hyperglycosylated PDGF fraction and a less glycosylated PDGF fraction; and

5 (b) isolating said hyperglycosylated PDGF from said mixture.

10 12. The method of claim 11 wherein said hyperglycosylated fraction is isolated using lectin affinity chromatography.

13. The method of claim 11 wherein said hyperglycosylated PDGF includes at least an average of 10 moles of carbohydrate per mole of dimer.

15 14. The method of claim 11 wherein said hyperglycosylated PDGF includes at least an average of 17 moles of carbohydrate per mole of dimer.

20 15. The method of claim 13 wherein said hyperglycosylated PDGF comprises PDGF B-B homodimer.

16. The method of claim 14 wherein said hyperglycosylated PDGF comprises PDGF B-B homodimer.

25 17. The method of claim 15 wherein said carbohydrate comprises mannose.

30 18. The method of claim 16 wherein said carbohydrate comprises mannose.

19. The method of claim 11 wherein said mixture is derived from yeast cells expressing PDGF.

20. A method of producing PDGF B-B homodimer having at least 17 moles of mannose per mole of dimer substantially free of less glycosylated PDGF comprising:

- (a) providing a mixture containing said PDGF B-B homodimer and less glycosylated PDGF; and
(b) isolating said PDGF B-B homodimer using lectin affinity chromatography.

21. The method of claim 20 wherein said PDGF is produced in yeast.

22. In a method of purifying recombinant PDGF from an expression media which comprises a hyperglycosylated PDGF fraction and a less glycosylated PDGF fraction, the improvement comprising isolating said hyperglycosylated PDGF fraction from said expression media.

23. The method of claim 22 wherein said hyperglycosylated PDGF is isolated using lectin affinity chromatography.

24. The method of claim 22 wherein said recombinant PDGF is purified from yeast expression media.

30

35

1/16

Translation of PDGF A Short Form

AGC	ATC	GAG	GAA	GCT	GTC	CCC	GCT	GTC	TGC	AAG	ACC	AGG	ACG	GTC	ATT
Ser	Ile	Glu	Glu	Ala	Val	Pro	Ala	Val	Cys	Lys	Thr	Arg	Thr	Val	Ile
1									10						
TAC	GAG	ATT	CCT	CGG	AGT	CAG	GTC	GAC	CCC	ACG	TCC	GCC	AAC	TTC	CTG
Tyr	Glu	Ile	Pro	Arg	Ser	Gln	Val	Asp	Pro	Thr	Ser	Ala	Asn	Phe	Leu
			20										30		
ATC	TGG	CCC	CCG	TGC	GTG	GAG	GTG	AAA	CGC	TGC	ACC	GGC	TGC	TGC	AAC
Ile	Trp	Pro	Pro	Cys	Val	Glu	Val	Lys	Arg	Cys	Thr	Gly	Cys	Cys	Asn
							40								
ACG	AGC	AGT	GTC	AAG	TGC	CAG	CCC	TCC	CGC	GTC	CAC	CAC	CGC	AGC	GTC
Thr	Ser	Ser	Val	Lys	Cys	Gln	Pro	Ser	Arg	Val	His	His	Arg	Ser	Val
	50										60				
AAG	GTG	GCC	AAG	GTG	GAA	TAC	GTC	AGG	AAG	AAG	CCA	AAA	TTA	AAA	GAA
Lys	Val	Ala	Lys	Val	Glu	Tyr	Val	Arg	Lys	Lys	Pro	Lys	Leu	Lys	Glu
					70										80
GTC	CAG	GTG	AGG	TTA	GAG	GAG	CAT	TTG	GAG	TGC	GCC	TGC	GCG	ACC	ACA
Val	Gln	Val	Arg	Leu	Glu	Glu	His	Leu	Glu	Cys	Ala	Cys	Ala	Thr	Thr
								90							
AGC	CTG	AAT	CCG	GAT	TAT	CGG	GAA	GAG	GAC	ACG	GAT	GTG	AGG		
Ser	Leu	Asn	Pro	Asp	Tyr	Arg	Glu	Glu	Asp	Thr	Asp	Val	Arg		
			100										110		

Translated Mol. Weight = 12517.32

Figure 1

SUBSTITUTE SHEET

2/16

Translation of PDGF A Long Form

AGC	ATC	GAG	GAA	GCT	GTC	CCC	GCT	GTC	TGC	AAG	ACC	AGG	ACG	GTC	ATT
Ser	Ile	Glu	Glu	Ala	Val	Pro	Ala	Val	Cys	Lys	Thr	Arg	Thr	Val	Ile
1									10						
TAC	GAG	ATT	CCT	CGG	AGT	CAG	GTC	GAC	CCC	ACG	TCC	GCC	AAC	TTC	CTG
Tyr	Glu	Ile	Pro	Arg	Ser	Gln	Val	Asp	Pro	Thr	Ser	Ala	Asn	Phe	Leu
			20										30		
ATC	TGG	CCC	CCG	TGC	GTG	GAG	GTG	AAA	CGC	TGC	ACC	GGC	TGC	TGC	AAC
Ile	Trp	Pro	Pro	Cys	Val	Glu	Val	Lys	Arg	Cys	Thr	Gly	Cys	Cys	Asn
							40								
ACG	AGC	AGT	GTC	AAG	TGC	CAG	CCC	TCC	CGC	GTC	CAC	CAC	CGC	AGC	GTC
Thr	Ser	Ser	Val	Lys	Cys	Gln	Pro	Ser	Arg	Val	His	His	Arg	Ser	Val
	50										60				
AAG	GTG	GCC	AAG	GTG	GAA	TAC	GTC	AGG	AAG	AAG	CCA	AAA	TTA	AAA	GAA
Lys	Val	Ala	Lys	Val	Glu	Tyr	Val	Arg	Lys	Lys	Pro	Lys	Leu	Lys	Glu
					70										80
GTC	CAG	GTG	AGG	TTA	GAG	GAG	CAT	TTG	GAG	TGC	GCC	TGC	GCG	ACC	ACA
Val	Gln	Val	Arg	Leu	Glu	Glu	His	Leu	Glu	Cys	Ala	Cys	Ala	Thr	Thr
								90							
AGC	CTG	AAT	CCG	GAT	TAT	CGG	GAA	GAG	GAC	ACG	GGA	AGG	CCT	AGG	GAG
Ser	Leu	Asn	Pro	Asp	Tyr	Arg	Glu	Glu	Asp	Thr	Gly	Arg	Pro	Arg	Glu
			100										110		
TCA	GGT	AAA	AAA	CGG	AAA	AGA	AAA	AGG	TTA	AAA	CCC	ACC			
Ser	Gly	Lys	Lys	Arg	Lys	Arg	Lys	Arg	Leu	Lys	Pro	Thr			
							120								

Translated Mol. Weight = 14307.74

Figure 2

3/16

```

TCT TTG GGT TCT TTG ACT ATC GCT GAA CCA GCT ATG ATC GCT GAA TGT
Ser Leu Gly Ser Leu Thr Ile Ala Glu Pro Ala Met Ile Ala Glu Cys
  1                                10

AAG ACT AGA ACT GAA GTT TTC GAA ATC TCC AGA AGA TTG ATC GAC AGA
Lys Thr Arg Thr Glu Val Phe Glu Ile Ser Arg Arg Leu Ile Asp Arg
      20                                30

ACT AAC GCT AAC TTC TTG GTT TGG CCA CCA TGT GTT GAA GTT CAA AGA
Thr Asn Ala Asn Phe Leu Val Trp Pro Pro Cys Val Glu Val Gln Arg
      40

TGT TCT GGT TGT TGT AAC AAC AGA AAC GTT CAA TGT AGA CCA ACT CAA
Cys Ser Gly Cys Cys Asn Asn Arg Asn Val Gln Cys Arg Pro Thr Gln
  50                                60

GTT CAA TTG AGA CCA GTT CAA GTT AGA AAG ATC GAA ATC GTT AGA AAG
Val Gln Leu Arg Pro Val Gln Val Arg Lys Ile Glu Ile Val Arg Lys
      70                                80

AAG CCA ATC TTC AAG AAG GCT ACT GTT ACT TTG GAA GAC CAC TTG GCT
Lys Pro Ile Phe Lys Lys Ala Thr Val Thr Leu Glu Asp His Leu Ala
      90

TGT AAG TGT GAA ACT GTC GCC GCT GCC AGG CCA GTT ACT TAA TAG
Cys Lys Cys Glu Thr Val Ala Ala Ala Arg Pro Val Thr OC
      100

```

Translated Mol. Weight = 12296.37

Figure 3

4/16

Sequence of the Human Platelet-Derived
Growth Factor A-Chain Clone Uppsala-13-1

```

GAATTCCGTC CGCAAATATG CAGAATTACC GGCCGGGTCG CTCCTGAAGC CAGCGCGGGG
AGGCAGCGCG GCGGCGGCCA GCACCGGGAA CGCACCGAGG AAGAAGCCCA GCCCCGCCC
TCCGCCCCTT CCGTCCCCAC CCCCATCCCC GCGGCCCAGG AGGCTCCCCG CGCTGGCGCG
CACTCCCTGT TTCTCCTCCT CCTGGCTGGC GCTGCCTGCC TCTCCGCACT CACTGCTCGC
CGGGCGCCGT CCGCCAGCTC CGTGCTCCCC GCGCCACCCT CCTCCGGGCC GCGCTCCCTA
AGGGATGGTA CTGATTTTCG CCGCCACAGG AGACCGGCTG GAGCGCCGCC CCGCGGCCTC
GCCTCTCCTC CGAGCAGCCA GCGCCTCGGG ACGCG ATG AGG ACC TTG GCT TGC
                                     Met Arg Thr Leu Ala Cys
                                     1

CTG CTG CTC CTC GGC TGC GGA TAC CTC GCC CAT GTT CTG GCC GAG GAA
Leu Leu Leu Leu Gly Cys Gly Tyr Leu Ala His Val Leu Ala Glu Glu
                                     10                                     20

GCC GAG ATC CCC CGC GAG GTG ATC GAG AGG CTG GCC CGC AGT CAG ATC
Ala Glu Ile Pro Arg Glu Val Ile Glu Arg Leu Ala Arg Ser Gln Ile
                                     30

CAC AGC ATC CGG GAC CTC CAG CGA CTC CTG GAG ATA GAC TCC GTA GGG
His Ser Ile Arg Asp Leu Gln Arg Leu Leu Glu Ile Asp Ser Val Gly
                                     40                                     50

AGT GAG GAT TCT TTG GAC ACC AGC CTG AGA GCT CAC GGG GTC CAT GCC
Ser Glu Asp Ser Leu Asp Thr Ser Leu Arg Ala His Gly Val His Ala
                                     60                                     70

ACT AAG CAT GTG CCC GAG AAG CGG CCC CTG CCC ATT CGG AGG AAG AGA
Thr Lys His Val Pro Glu Lys Arg Pro Leu Pro Ile Arg Arg Lys Arg
                                     80

AGC ATC GAG GAA GCT GTC CCC GCT GTC TGC AAG ACC AGG ACG GTC ATT
Ser Ile Glu Glu Ala Val Pro Ala Val Cys Lys Thr Arg Thr Val Ile
                                     90                                     100

TAC GAG ATT CCT CGG AGT CAG GTC GAC CCC ACG TCC GCC AAC TTC CTG
Tyr Glu Ile Pro Arg Ser Gln Val Asp Pro Thr Ser Ala Asn Phe Leu
                                     110

ATC TGG CCC CCG TGC GTG GAG GTG AAA CGC TGC ACC GGC TGC TGC AAC
Ile Trp Pro Pro Cys Val Glu Val Lys Arg Cys Thr Gly Cys Cys Asn
                                     120                                     130

```

Figure 4 (Sheet 1 of 2)

SUBSTITUTE SHEET

5/16

ACG AGC AGT GTC AAG TGC CAG CCC TCC CGC GTC CAC CAC CGC AGC GTC
Thr Ser Ser Val Lys Cys Gln Pro Ser Arg Val His His Arg Ser Val
140 150

AAG GTG GCC AAG GTG GAA TAC GTC AGG AAG AAG CCA AAA TTA AAA GAA
Lys Val Ala Lys Val Glu Tyr Val Arg Lys Lys Pro Lys Leu Lys Glu
160

GTC CAG GTG AGG TTA GAG GAG CAT TTG GAG TGC GCC TGC GCG ACC ACA
Val Gln Val Arg Leu Glu Glu His Leu Glu Cys Ala Cys Ala Thr Thr
170 180

AGC CTG AAT CCG GAT TAT CGG GAA GAG GAC ACG GAT GTG AGG TGA
Ser Leu Asn Pro Asp Tyr Arg Glu Glu Asp Thr Asp Val Arg OP
190

GGATGAGCCG CAGCCCTTTC CTGGGACATG GATGTACATG GCGTGTTACA TTCCTGAACC
TACTATGTAC GGTGCTTTAT TGCCAGTGTG CGGTCTTTGT TCTCCTCCGT GAAAAACTGT
GTCCGAGAAC ACTCGGGAGA ACAAAGAGAC AGTGCACATT TGTTTAATGT GACATCAAAG
CAAGTATTGT AGCACTCGGT GAAGCAGTAA GAAGCTTCCT TGTCAAAAAG AGAGAGAGAG
AAAAGAAAAA AAAAGGAATT C

Translated Mol. Weight = 22256.17

Figure 4 (Sheet 2 of 2)

6/16

Sequence of the Human Platelet-Derived
Growth Factor A-Chain Clone Uppsala-D1

```

GAATTCCGTC CGCAAATATG CAGAATTACC GGCCGGGTCG CTCCTGAAGC CAGCGCGGGG
AGGCAGCGCG GCGGCGGCCA GCACCGGGAA CGCACCGAGG AAGAAGCCCA GCCCCGCCC
TCCGCCCCCTT CCGTCCCCAC CCCCATCCCC GCGGCCCAGG AGGCTCCCCG CGCTGGCGCG
CACTCCCTGT TTCTCCTCCT CCTGGCTGGC GCTGCCTGCC TCTCCGCACT CACTGCTCGC
CGGGCGCCGT CCGCCAGCTC CGTGCTCCCC GCGCCACCCT CCTCCGGGCC GCGTCCCTA
AGGGATGGTA CTGATTTTCG CCGCCACAGG AGACCGGCTG GAGCGCCGCC CCGCGGCCTC
GCCTCTCCTC CGAGCAGCCA GCGCCTCGGG ACGCG ATG AGG ACC TTG GCT TGC
                                     Met Arg Thr Leu Ala Cys
                                     1

CTG CTG CTC CTC GGC TGC GGA TAC CTC GCC CAT GTT CTG GCC GAG GAA
Leu Leu Leu Leu Gly Cys Gly Tyr Leu Ala His Val Leu Ala Glu Glu
                                     10                                     20

GCC GAG ATC CCC CGC GAG GTG ATC GAG AGG CTG GCC CGC AGT CAG ATC
Ala Glu Ile Pro Arg Glu Val Ile Glu Arg Leu Ala Arg Ser Gln Ile
                                     30

CAC AGC ATC CGG GAC CTC CAG CGA CTC CTG GAG ATA GAC TCC GTA GGG
His Ser Ile Arg Asp Leu Gln Arg Leu Leu Glu Ile Asp Ser Val Gly
                                     40                                     50

AGT GAG GAT TCT TTG GAC ACC AGC CTG AGA GCT CAC GGG GTC CAT GCC
Ser Glu Asp Ser Leu Asp Thr Ser Leu Arg Ala His Gly Val His Ala
                                     60                                     70

ACT AAG CAT GTG CCC GAG AAG CGG CCC CTG CCC ATT CGG AGG AAG AGA
Thr Lys His Val Pro Glu Lys Arg Pro Leu Pro Ile Arg Arg Lys Arg
                                     80

AGC ATC GAG GAA GCT GTC CCC GCT GTC TGC AAG ACC AGG ACG GTC ATT
Ser Ile Glu Glu Ala Val Pro Ala Val Cys Lys Thr Arg Thr Val Ile
                                     90                                     100

TAC GAG ATT CCT CGG AGT CAG GTC GAC CCC ACG TCC GCC AAC TTC CTG
Tyr Glu Ile Pro Arg Ser Gln Val Asp Pro Thr Ser Ala Asn Phe Leu
                                     110

ATC TGG CCC CCG TGC GTG GAG GTG AAA CGC TGC ACC GGC TGC TGC AAC
Ile Trp Pro Pro Cys Val Glu Val Lys Arg Cys Thr Gly Cys Cys Asn
                                     120                                     130

ACG AGC AGT GTC AAG TGC CAG CCC TCC CGC GTC CAC CAC CGC AGC GTC
Thr Ser Ser Val Lys Cys Gln Pro Ser Arg Val His His Arg Ser Val
                                     140                                     150

```

Figure 5 (Sheet 1 of 2)

SUBSTITUTE SHEET

7/16

AAG GTG GCC AAG GTG GAA TAC GTC AGG AAG AAG CCA AAA TTA AAA GAA
Lys Val Ala Lys Val Glu Tyr Val Arg Lys Lys Pro Lys Leu Lys Glu
160

GTC CAG GTG AGG TTA GAG GAG CAT TTG GAG TGC GCC TGC GCG ACC ACA
Val Gln Val Arg Leu Glu Glu His Leu Glu Cys Ala Cys Ala Thr Thr
170 180

AGC CTG AAT CCG GAT TAT CGG GAA GAG GAC ACG GGA AGG CCT AGG GAG
Ser Leu Asn Pro Asp Tyr Arg Glu Glu Asp Thr Gly Arg Pro Arg Glu
190

TCA GGT AAA AAA CGG AAA AGA AAA AGG TTA AAA CCC ACC TAA AGCAGCCA
Ser Gly Lys Lys Arg Lys Arg Lys Arg Leu Lys Pro Thr OC
200 210

ACCAGATGTG AGGTGAGGAT GAGCCGCAGC CCTTTCCTGG GACATGGATG TACATGGCGT
GTTACATTCC TGAACCTACT ATGTACGGTG CTTTATTGCC AGTGTGCGGT CTTTGTTCCTC
CTCCGTGAAA AACTGTGTCC GAGAACACTC GGGAGAACAA AGAGACAGTG CACATTTGTT
TAATGTGACA TCAAAGCAAG TATTGTAGCA CTCGGTGAAG CAGTAAGAAG CTTTCCTTGTC
AAAAAGAGAG AGAGAGAAAA GAAAAAAAAA GGAATTC

Translated Mol. Weight = 24046.60

Figure 5 (Sheet 2 of 2)

8/16




Figure 6

9/16




Figure 7

10/16




Figure 8

11/16





Figure 9



13/16




Figure 11

14/16




Figure 12

15/16

Sequence of SV40 early promoter, polylinker, and SV40
poly A addition region from pSV7d

```

| 1/2 PVU11 site SV40 early promoter ---->
CTGTGGAATG TGTGTCAGTT AGGGTGTGGA AAGTCCCCAG GCTCCCCAGC AGGCAGAAGT
GACACCTTAC ACACAGTCAA TCCCACACCT TTCAGGGGTC CGAGGGGTCG TCCGTCTTCA

61 ATGCAAAGCA TGCATCTCAA TTAGTCAGCA AGGAAAGTCC CCAGGCTCCC CAGCAGGCAG
TACGTTTCGT ACGTAGAGTT AATCAGTCGT TCCTTTCAGG GGTCCGAGGG GTCGTCCGTC

68 SPH1

121 AAGTATGCAA AGCATGCATC TCAATTAGTC AGCAACCATA GTCCCGCCCC TAACTCCGCC
TTCATACGTT TCGTACGTAG AGTTAATCAG TCGTTGGTAT CAGGGCGGGG ATTGAGGCGG

132 SPH1

181 CATCCCGCCC CTAAGTCCGC CCAGTTCCGC CCATTCTCCG CCCCATGGCT GACTAATTTT
GTAGGGCGGG GATTGAGGCG GGTCAAGGCG GGTAAGAGGC GGGGTACCGA CTGATTAAAA

223 NcoI,

241 TTTTATTAT GCAGAGGCCG AGGCCGCCTC GGCCTCTGAG CTATTCCAGA AGTAGTGAAG
AAAATAAATA CGTCTCCGGC TCCGGCGGGAG CCGGAGACTC GATAAGGTCT TCATCACTTC

263 BglI

|-----polylinker-----> OC OP OP
301 AGGCTTTTTT GGAGGAGATC GAATTCCTCG GTCTAGAGGA TCCGTCGACC TAGATAAGTA
TCCGAAAAAA CCTCCTCTAG CTTAAGGGCC CAGATCTCCT AGGCAGCTGG ATCTATTCAT

321 EcoRI, 326 SmaI XbaI, 332 XbaI, 338 BamHI, 344 SalI,

361 ATGATCATAA TCAGCCATAT CACATCTGTA GAGGTTTTAC TTGCTTTAAA AAACCTCCCA
TACTAGTATT AGTCGGTATA GTGTAGACAT CTCCAAAATG AACGAAATT TTTGGAGGGT

362 BclI, 405 DraI,

421 CACCTCCCCC TGAACCTGAA ACATAAAATG AATGCAATTG TTGTTGTTAA CTGTTTATT
GTGGAGGGGG ACTTGACTT TGTATTTTAC TTACGTTAAC AACACAATT GAACAAATAA

466 HpaI

481 GCAGCTTATA ATGTTACAA ATAAAGCAAT AGCATCACA ATTTCACAA TAAAGCATTT
CGTCGAATAT TACCAATGTT TATTTCTGTA TCGTAGTGT TAAAGTGT TTTTCGTAA

End of SV40----->|| -pBR322 (pos. 4210)->
541 TTTTCACTGC ATTCTAGTTG TGGTTTGTC AACTCATCC GCTCATGAGA CAATAACCCT
AAAAGTGACG TAAGATCAAC ACCAAACAGG TTTGAGTAGG CGAGTACTCT GTTATTGGGA

```

Figure 13

16/16





Figure 14

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/02766

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): C07K 3/12, 3/28 U.S. CL.: 530/350; 435/172.3, 69.9, 69.4		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S.	530/350 435/172.3, 69.9, 69.4	
Documentation Searched other than Minimum Documentation to the extent that such documents are included in the fields searched *		
Databases: Dialog (files 5, 399, 155, 154, 357, 72) Automated Patent System (File USPAT, 1971-1991)		
III. DOCUMENTS CONSIDERED TO BE RELEVANT *		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	Virology, Volume 164, issued 1988, KLEIN ET AL., "Highly glycosylated PDGF-like Molecule Secreted by Simian Sarcoma Virus-Transformed Cell", pages 403-410 (See entire document).	1-5
Y	US, A, 4,845,075 (MURRAY ET AL.) 04 July 1989, see entire document.	6-24
Y	US, A, 4,766,073 (MURRAY ET AL.) 23 August 1988, see entire document.	6-24
Y	US, A, 4,849,407 (MURRAY ET AL.) 18 July 1989, see entire document.	6-24
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claims) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Making of this International Search Report
28 June 1991		18 JUL 1991
International Searching Authority		Signature of Authorizing Officer
ISA/US		<div style="text-align: center;">  Lynette F. Smith (vsh) </div>